Tivity Health (TVTY) 10-K 26 Feb 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2018	Feb. 21, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	TIVITY HEALTH, INC.
Entity Central Index Key	704,415
Current Fiscal Year End Date	--12-31
Trading Symbol	TVTY
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 1.4
Entity Common Stock, Shares Outstanding		41,071,362
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,933	$ 28,440
Accounts receivable, net	67,139	55,113
Prepaid expenses	3,655	3,444
Cash convertible notes hedges		134,079
Income taxes receivable	720	39
Other current assets	4,658	2,180
Total current assets	78,105	223,295
Property and equipment, net of accumulated depreciation of $30,711 and $28,533, respectively	16,341	10,658
Long-term deferred tax asset		25,166
Intangible assets, net	29,049	29,049
Goodwill, net	334,680	334,680
Other assets	23,904	13,315
Total assets	482,079	636,163
Current liabilities:
Accounts payable	29,103	26,804
Accrued salaries and benefits	6,512	15,018
Accrued liabilities	43,145	34,511
Cash conversion derivative		134,079
Current portion of long-term debt	57	145,959
Current portion of long-term liabilities	2,255	2,262
Total current liabilities	81,072	358,633
Long-term debt	30,589
Long-term deferred tax liability	319
Other long-term liabilities	1,098	5,577
Stockholders' equity:
Preferred stock $.001 par value, 5,000,000 shares authorized, none outstanding
Common stock $.001 par value, 120,000,000 shares authorized, 41,049,418 and 39,729,580 shares outstanding, respectively	41	40
Additional paid-in capital	347,487	349,243
Retained earnings (accumulated deficit)	49,655	(49,148)
Treasury stock, at cost, 2,254,953 shares in treasury	(28,182)	(28,182)
Total stockholders' equity	369,001	271,953
Total liabilities and stockholders' equity	$ 482,079	$ 636,163

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Accumulated depreciation	$ 30,711	$ 28,533
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares outstanding (in shares)	41,049,418	39,729,580
Treasury stock (in shares)	2,254,953	2,254,953

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues		$ 606,299	$ 556,942	$ 500,998
Cost of services (exclusive of depreciation and amortization of $4,109, $2,802, and $3,468, respectively, included below)		432,714	395,605	357,120
Selling, general and administrative expenses		35,113	34,361	39,478
Depreciation and amortization		4,667	3,357	4,085
Restructuring and related charges		124	3,223	4,933
Operating income		133,681	120,396	95,382
Interest expense		8,733	15,613	17,318
Income before income taxes		124,948	104,783	78,064
Income tax expense		27,046	43,553	21,973
Income from continuing operations		97,902	61,230	56,091
Income (loss) from discontinued operations, net of income tax		901	2,485	(184,706)
Net income (loss)		98,803	63,715	(128,615)
Less: net income (loss) attributable to non-controlling interest		0	0	496
Net income (loss) attributable to Tivity Health, Inc.		$ 98,803	$ 63,715	$ (129,111)
Earnings (loss) per share attributable to Tivity Health, Inc. - basic:
Continuing operations		$ 2.44	$ 1.56	$ 1.52
Discontinued operations		0.02	0.06	(5.01)
Net income (loss)	[1]	2.47	1.62	(3.49)
Earnings (loss) per share attributable to Tivity Health, Inc. – diluted:
Continuing operations		2.27	1.44	1.47
Discontinued operations		0.02	0.06	(4.86)
Net income (loss)		$ 2.29	$ 1.50	$ (3.39)
Comprehensive income (loss)		$ 98,803	$ 68,217	$ (128,878)
Weighted average common shares and equivalents:
Basic		40,078	39,357	36,999
Diluted		43,073	42,547	38,075
[1]	Figures may not add due to rounding.

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Cost of services, depreciation and amortization	$ 4,109	$ 2,802	$ 3,468

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 63,715	$ (128,615)
Other comprehensive income (loss), net of tax
Net change in fair value of interest rate swaps, net of tax		239
Foreign currency translation adjustment, net of tax	1,458	(502)
Release of cumulative translation adjustment to loss from discontinued operations due to substantial liquidation of foreign entity	3,044
Total other comprehensive income (loss), net of tax	4,502	(263)
Comprehensive income (loss)	$ 68,217	$ (128,878)

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Treasury Stock	Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2015	$ 280,590	$ 0	$ 36	$ 303,687	$ 9,288	$ (28,182)	$ (4,239)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)	(128,878)	0	0	0	(128,615)	0	(263)
Exercise of stock options	10,002	0	2	10,000	0	0	0
Tax effect of stock options and restricted stock units	(8,947)	0	0	(8,947)	0	0	0
Share-based employee compensation expense	17,538	0	0	17,538	0	0	0
Issuance of CareFirst Warrants	192	0	0	192	0	0	0
Conversion of CareFirst Convertible Note	20,000	0	1	19,999	0	0	0
Settlement of non-controlling interest	(1,199)	0	0	(1,199)	0	0	0
Balance at Dec. 31, 2016	189,298	0	39	341,270	(119,327)	(28,182)	(4,502)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of a change inaccounting principle – adoptionof ASU 2016-09 | Accounting Standards Update 2016-09 [Member]	6,538	0	0	74	6,464	0	0
Comprehensive income (loss)	68,217	0	0	0	63,715	0	4,502
Exercise of stock options	5,723	0	1	5,722	0	0	0
Tax withholding for share-based compensation	(4,481)	0	0	(4,481)	0	0	0
Share-based employee compensation expense	6,658	0	0	6,658	0	0	0
Balance at Dec. 31, 2017	271,953	0	40	349,243	(49,148)	(28,182)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)	98,803	0	0	0	98,803	0	0
Tax withholding for share-based compensation	(9,762)	0	0	(9,762)	0	0	0
Share-based employee compensation expense	6,097	0	0	6,097	0	0	0
Exercise of stock options and Warrants	1,910	0	1	1,909	0	0	0
Balance at Dec. 31, 2018	$ 369,001	$ 0	$ 41	$ 347,487	$ 49,655	$ (28,182)	$ 0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net income from continuing operations	$ 97,902	$ 61,230	$ 56,091
Income (loss) from discontinued operations, net of income tax	901	2,485	(184,706)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	4,667	3,357	31,292
Amortization of deferred loan costs	1,152	2,887	2,209
Amortization of debt discount	4,140	8,001	7,564
Share-based employee compensation expense	6,097	6,658	17,538
Loss on release of cumulative translation adjustment		3,044
Equity in income from joint ventures			(271)
Deferred income taxes	25,485	40,935	(75,942)
(Increase) decrease in accounts receivable, net	(12,311)	(3,939)	8,330
Decrease in other current assets	1,610	820	2,819
Decrease increase in accounts payable	(95)	(407)	(3,376)
Decrease in accrued salaries and benefits	(10,314)	(6,061)	(1,056)
Decrease in other current liabilities	(11,802)	(6,436)	(4,825)
Other	2,611	(2,565)	(7,425)
Net cash flows provided by operating activities	108,739	105,276	45,601
Cash flows from investing activities:
Acquisition of property and equipment	(9,053)	(5,910)	(14,474)
Investment in joint ventures			(1,298)
Proceeds from sale of MeYou Health	1,416		5,156
Payments related to sale of TPHS business			(27,469)
Other			(787)
Net cash flows used in investing activities	(7,637)	(5,910)	(38,872)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	253,425	373,450	515,666
Payments of long-term debt	(373,536)	(449,084)	(527,115)
Proceeds from settlement of cash convertible notes hedges	141,246
Payments related to settlement of cash conversion derivative	(141,246)
Payments related to tax withholding for share-based compensation	(9,762)	(4,481)	(7,699)
Exercise of stock options	1,910	5,722	10,002
Deferred loan costs		(2,452)	(424)
Change in cash overdraft and other	410	2,533	2,834
Net cash flows used in financing activities	(127,553)	(74,312)	(6,736)
Effect of exchange rate changes on cash	(56)	1,784	(261)
Less: net (decrease) increase in discontinued operations cash and cash equivalents			(1,637)
Net increase (decrease) in cash and cash equivalents	(26,507)	26,838	1,369
Cash and cash equivalents, beginning of period	28,440	1,602	233
Cash and cash equivalents, end of period	1,933	28,440	1,602
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	4,099	4,727	7,474
Cash paid during the period for income taxes, net of refunds	3,339		1,458
Noncash activities:
Issuance of CareFirst Warrants			192
Assets acquired through capital lease obligation	209
Conversion of CareFirst Convertible Note			20,000
MeYou Health
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
(Gain) loss on sale	(1,416)		5,325
TPHS Business
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
(Gain) loss on sale	$ 112	$ (4,733)	$ 192,034

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Tivity Health, Inc. was founded and incorporated in Delaware in 1981. Through our three programs, SilverSneakers ® ® TM Our results from continuing operations do not include the results of the total population health services ("TPHS") business, which we sold effective July 31, 2016. The TPHS business included our partnerships with Blue Zones, LLC and Dr. Dean Ornish (the Blue Zones Project by Healthways™ and Dr. Dean Ornish's Program for Reversing Heart Disease™, respectively), our joint venture with Gallup, Inc., Navvis Healthcare, LLC (“Navvis”), MeYou Health, LLC (“MeYou Health”), and our international operations, including our joint venture with SulAmérica. While Navvis and MeYou Health were part of our TPHS business, they were sold separately to other buyers in November 2015 and June 2016, respectively. Results of operations for the TPHS business have been classified as discontinued operations for all periods presented in the accompanying consolidated financial statements. See Note 4 for further information on discontinued operations. On March 11, 2015, we formed a joint venture with SulAmérica, one of the largest independent insurers in Brazil, to sell total population health services to the Brazilian market. With its contribution, SulAmérica acquired a 49% interest in the joint venture, Healthways Brasil Servicos de Consultoria LTDA ("Healthways Brazil"). We determined that our interest in Healthways Brazil represented a controlling financial interest and, therefore, prior to selling the TPHS business, consolidated the financial statements of Healthways Brazil and presented a non-controlling interest for the portion owned by SulAmérica. The net assets and results of operations of Healthways Brazil were part of the sale of the TPHS business and are included within discontinued operations in the accompanying consolidated financial statements. Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In our opinion, the accompanying consolidated financial statements of Tivity Health, Inc. and its wholly-owned subsidiaries (collectively, “Tivity Health,” the “Company,” or such terms as “we,” “us,” or “our”) reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement. We have reclassified certain items in prior periods to conform to current classifications. a. Principles of Consolidation – See discussion above regarding the TPHS business, including a non-controlling interest. We have eliminated all intercompany profits, transactions, and balances. b. Cash and Cash Equivalents - Cash and cash equivalents primarily include cash on deposit. c. Accounts Receivable, net - Accounts receivable includes billed and unbilled amounts. Billed receivables represent fees that are contractually due for services performed, net of allowances for doubtful accounts (reflected as selling, general and administrative expenses). Allowances for doubtful accounts were $0 at December 31, 2018 and 2017. Historically, we have experienced minimal instances of customer non-payment and therefore consider our accounts receivable to be collectible; however, we provide reserves, when appropriate, for doubtful accounts on a specific identification basis. Unbilled receivables primarily represent fees recognized for monthly member utilization of fitness facilities under our SilverSneakers fitness solution, billed one month in arrears. d. Property and Equipment - Property and equipment is carried at cost and includes expenditures that increase value or extend useful lives. We recognize depreciation using the straight-line method over useful lives of three to seven years for computer software and hardware and four to seven years for furniture and other office equipment. Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the life of the lease, which ranges from two to fifteen years. Depreciation expense for the years ended December 31, 2018, 2017, and 2016 was $4.7 million, $3.4 million, and $3.6 million, respectively, including depreciation of assets recorded under capital leases. e. Other Assets - Other assets consist primarily of shares of common stock of Sharecare (see Note 4), which are accounted for as a cost method investment, and customer incentives. We have elected f. Intangible Assets - Intangible assets subject to amortization include customer contracts, acquired technology, and distributor and provider networks, which we amortized on a straight-line basis over estimated useful lives ranging from three to ten years. All intangible assets subject to amortization were fully amortized at December 31, 2018 and 2017. We assess the potential impairment of intangible assets subject to amortization whenever events or changes in circumstances indicate that the carrying values may not be recoverable. If we determine that the carrying value of identifiable intangible assets may not be recoverable, we calculate any impairment using an estimate of the asset's fair value based on the estimated price that would be received to sell the asset in an orderly transaction between market participants. Intangible assets not subject to amortization at December 31, 2018 and 2017 consist of a trade name of $29.0 million. We review intangible assets not subject to amortization on an annual basis or more frequently whenever events or circumstances indicate that the assets might be impaired. See Note 7 for further information on intangible assets. g. Goodwill - We recognize goodwill for the excess of the purchase price over the fair value of tangible and identifiable intangible net assets of businesses that we acquire. We review goodwill for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (during the fourth quarter of the fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. We have a single reporting unit. As part of the impairment evaluation, we may elect to perform a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If w e elect not to perform a qualitat i ve assessment or we determine that it is more l i kely than not that the fair value of the rep o rting unit is less than its c a rryi n g value, we perform a quantitative review as descr i bed be l ow. Dur i ua d o If we determine that the carrying value of goodwill is impaired, we calculate any impairment using a fair-value based goodwill impairment test as required by U.S. GAAP. The fair value of a reporting unit is the price that would be received upon a sale of the unit as a whole in an orderly transaction between market participants at the measurement date. h. Accounts Payable - Accounts payable consists of short-term trade obligations and includes cash overdrafts attributable to disbursements not yet cleared by the bank. i. Accrued Liabilities – Accrued liabilities primarily include amounts owed for estimated member visits to network locations (which actual visit data is typically received approximately one month in arrears) j. Income Taxes - We file a consolidated federal income tax return that includes all of our wholly-owned subsidiaries. U.S. GAAP generally require that we record deferred income taxes for the tax effect of differences between the book and tax bases of our assets and liabilities. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are expected to be realized. When we determine that it is more likely than not that we will be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset is made and reflected in income. k. Revenue Recognition - On January 1, 2018, we adopted Accounting Standards Update (“ASU”) No. 2014-09 (as discussed under “Recent Relevant Accounting Standards” below) using the modified retrospective transition method applied to contracts that were not completed as of January 1, 2018. See Note 3 for a further discussion of revenue recognition. l. Earnings (Loss) Per Share – We calculate basic earnings (loss) per share using weighted average common shares outstanding during the period. We calculate diluted earnings (loss) per share using weighted average common shares outstanding during the period plus the effect of all dilutive potential common shares outstanding during the period unless the impact would be anti-dilutive. See Note 15 for a reconciliation of basic and diluted earnings (loss) per share. m. Share-Based Compensation – We recognize all share-based payments to employees in the consolidated statements of operations over the required vesting period based on estimated fair values at the date of grant. See Note 14 for further information on share-based compensation. n. Management Estimates – In preparing our consolidated financial statements in conformity with U.S. GAAP, management must make estimates and assumptions that affect: (1) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and (2) the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Relevant Accounting Stan

Recent Relevant Accounting Standards	12 Months Ended
	Dec. 31, 2018
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Relevant Accounting Standards	2. Re c o a d On January 1, 2018, we adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” (“ASC Topic 606”) using the modified retrospective method, pursuant to which we applied ASC Topic 606 to (i) all new contracts entered into after January 1, 2018 and (ii) contracts that were not completed as of January 1, 2018. In accordance with this approach, our results for periods prior to January 1, 2018 were not revised and continue to be reported in accordance with our historical accounting under ASC Topic 605, “Revenue Recognition.” For contracts that were modified prior to January 1, 2018, we have not retrospectively restated the contract for those modifications in accordance with the contract modification guidance in ASC 606-10-25-12 and ASC 606-10-25-13 but instead, using the practical expedient available under ASC 606-10-65-1(f)(4), have reflected the aggregate effect of all modifications when identifying the satisfied and unsatisfied performance obligations, determining the transaction price, and allocating the transaction price. The cumulative impact of our adoption of ASC Topic 606 was not material to record as of January 1, 2018, and there was no material impact on our consolidated income statement, balance sheet, or cash flows. For example, we do not have any material contract assets or contract liabilities as defined under ASC Topic 606. In addition, the incremental costs of obtaining a contract with a customer (for example, sales commissions) that would have been recognized as an asset on January 1, 2018 or on December 31, 2018 were not material to record. See Note 3 for a further discussion of revenue recognition. On January 1, 2018, we adopted ASU No. 2016-15, “Statement of Cash Flows” (Topic 230) (“ASU 2016-15”). ASU 2016-15 addresses how certain cash receipts and cash payments are presented and classified in the statement of cash flows and is to be applied using a retrospective approach. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures and did not result in a reclassification to items in prior periods. On January 1, 2018, we adopted ASU No. 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”), which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 is to be applied prospectively to awards modified on or after January 1, 2018. The adoption of this standard did not have an impact on our consolidated financial statements and related disclosures. In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, “Leases” (“ASU 2016-02” or “ASC 842”), which requires that lessees recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position, and was effective for us on January 1, 2019. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. ASC 842 originally required entities to use a modified retrospective transition method in which companies would initially apply ASC 842 and recognize an adjustment for the effects of the transition as of the beginning of the earliest comparative period presented (January 1, 2017 for the Company). In July 2018, the FASB issued ASU No. 2018-11, “Leases (Topic 842): Targeted Improvements”, which amends ASC 842 to allow entities to change the date of initial application to the beginning of the period of adoption (January 1, 2019 for the Company), with no requirement to recast comparative periods. We adopted ASC 842 as of January 1, 2019 and are electing to recognize the cumulative effect of initially applying the standard as an adjustment to beginning retained earnings as of January 1, 2019. The significant majority of our leases are classified as operating leases. Although we are still finalizing our analysis, we expect the new lease standard to have a material effect on our consolidated financial statements. The most significant effects relate to our recognition of new right-of-use assets and lease liabilities. We do not expect ASC 842 to have a material impact on net income or the statement of cash flows. In addition, we elected the following practical expedients available under ASC 842: (1) the package of practical expedients whereby we are not required to reassess upon adoption of ASC 842 (a) whether a contract is or contains a lease, (b) lease classification, and (c) initial direct costs (ASC 842-10-65-1(f)); and (2) the short-term lease measurement and recognition exemption (ASC 842-20-25-2). ASC 842 will also require significant new disclosures about leasing activity . In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other” (“ASU 2017-04”), which simplifies the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. ASU 2017-04 is effective for annual and interim impairment tests in fiscal years beginning after December 15, 2019 and is required to be applied prospectively. Early adoption is allowed for annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not anticipate that adopting this standard will have an impact on our consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC 820. ASU 2018-13 is effective for fiscal years beginning on or after December 15, 2019, including interim periods therein, and is generally required to be applied retrospectively, except for certain components that are to be applied prospectively. Early adoption is permitted for any eliminated or modified disclosures. We do not anticipate that adopting this standard will have a material impact on our disclosures. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires companies to measure credit losses for financial assets held at the reporting date utilizing a methodology that reflects current expected credit losses over the lifetime of such assets. ASU 2016-13 is effective for the Company on January 1, 2020 and is generally required to be applied using the modified retrospective approach, with limited exceptions for specific instruments. We do not anticipate that adopting this standard will have an impact on our consolidated financial statements and related disclosures.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2018
Revenue From Contract With Customer [Abstract]
Revenue Recognition	3. Revenue Recognition Beginning in 2018, we account for revenue from contracts with customers in accordance with ASC Topic 606. The unit of account in ASC Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided over a period of time. ASC Topic 606 requires that a contract's transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when or as the performance obligation is satisfied. We earn revenue from our three programs, SilverSneakers senior fitness, Prime Fitness and WholeHealth Living. We provide the SilverSneakers senior fitness program to members of Medicare Advantage and Medicare Supplement plans through our contracts with such plans. We offer Prime Fitness, a fitness facility access program, through contracts with employers, commercial health plans, and other sponsoring organizations that allow their members to individually purchase the program. We sell our WholeHealth Living program primarily to health plans. The significant majority of our customer contracts contain one performance obligation - to stand ready to provide access to our network of fitness locations and fitness programming - which is satisfied over time as services are rendered each month over the contract term. There are generally no performance obligations that are unsatisfied at the end of a particular month. There was no material revenue recognized during the year ended December 31, 2018 from performance obligations satisfied in a prior period. Our fees are variable month to month and are generally billed per member per month (“PMPM”) or billed based on a combination of PMPM and member visits to a network location. We bill PMPM fees by multiplying the contractually negotiated PMPM rate by the number of members eligible for or receiving our services during the month. We bill for member visits approximately one month in arrears once actual member visits are known. Payments from customers are typically due within 30 days of invoice date. When material, we capitalize costs to obtain contracts with customers and amortize them over the expected recovery period. Our customer contracts include variable consideration, which is allocated to each distinct month over the contract term based on eligible members and/or member visits each month. The allocated consideration corresponds directly with the value to our customers of our services completed for the month. Under the majority of our contracts, we recognize revenue each month using the practical expedient available under ASC 606-10-55-18, which provides that revenue is recognized in the amount for which we have the right to invoice. Although we evaluate our financial performance and make resource allocation decisions based upon the results of our single operating and reportable segment, we believe the following information depicts how our revenues and cash flows are affected by economic factors. For the year ended December 31, 2018, revenue from our SilverSneakers program, which is predominantly contracted with Medicare Advantage and Medicare Supplement plans, comprised approximately 80% of our consolidated revenues, while revenue from our Prime Fitness and WholeHealth Living programs comprised approximately 17% and 3%, respectively, of our consolidated revenues. Sales and usage-based taxes are excluded from revenues.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2018
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	4 . Discontinued Operations On July 27, 2016, we entered into a Membership Interest Purchase Agreement (the "Purchase Agreement") with Sharecare, Inc. ("Sharecare") and Healthways SC, LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company, pursuant to which Sharecare acquired the TPHS business, which closed effective July 31, 2016 ("Closing"). At Closing, Sharecare delivered to the Company an Adjustable Convertible Equity Right (the "ACER") with an initial face value of $30.0 million. The ACER became convertible into shares of common stock of Sharecare on July 31, 2018 at an initial conversion price of $249.87 per share, subject to customary adjustment for stock splits, stock dividends and other reorganizations of Sharecare. The Purchase Agreement provided for post-closing adjustments based on, among other things, any successful claims for indemnification by Sharecare which may have resulted in a reduction in the face amount of the ACER, At December 31, 2017, we recorded the $39.8 million face value of the ACER at an estimated carrying value of $10.8 million, which was classified as an equity receivable included in other long-term assets. Upon conversion of the ACER in October 2018, we obtained 159,309 shares of Sharecare common stock, which continue to be recorded in other long-term assets at a carrying value of $10.8 million. There are certain restrictions related to selling or transferring this stock. These shares may not be sold or otherwise transferred except (i) for cash subject to the right of first refusal by Sharecare and/or one or more of its shareholders (in each case, at their option), or (ii) with the consent of Sharecare’s shareholders holding at least a majority of Sharecare stock, or (iii) pursuant to certain other exemptions. The following table presents financial results of the TPHS business included in “income (loss) from discontinued operations" for the years ended December 31, 2018, 2017, and 2016. Year Ended December 31, (In thousands) 2018 2017 2016 Revenues $ — $ — $ 151,780 Cost of services 30 427 173,302 Selling, general & administrative expenses 48 349 18,594 Depreciation and amortization — — 27,207 Restructuring and related charges — — 8,626 Equity in income from joint ventures — 98 243 Pretax loss on discontinued operations (78 ) (678 ) (75,706 ) Pretax loss on release of cumulative translation adjustment (1) — (3,044 ) — Pretax gain (loss) on sale of MeYou Health business (2) 1,416 — (4,826 ) Pretax income (loss) on sale of TPHS business (112 ) 4,733 (202,095 ) Total pretax income (loss) on discontinued operations 1,226 1,011 (282,627 ) Income tax expense (benefit) 325 (1,474 ) (3) (97,921 ) Income (loss) from discontinued operations, net of income tax $ 901 $ 2,485 $ (184,706 ) (1) During the second quarter of 2017, we substantially liquidated foreign entities that were part of our TPHS business, resulting in a release of the cumulative translation adjustment of $3.0 million into loss from discontinued operations. (2) Includes $1.4 million received during the three months ended June 30, 2018 from a release of escrow funds related to the sale of MeYou Health, LLC in June 2016. ( 3 ) Income tax benefit for the year ended December 31, 2017 includes the effect of a change in the estimate of net U.S. tax incurred in 2016 on foreign activity classified as discontinued operations. The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows: Year Ended December 31, (In thousands) 2018 2017 2016 Depreciation and amortization $ — $ — $ 27,207 Capital expenditures — — 10,258 Share-based compensation — — 10,144

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Property and Equipment	5 . Property and Equipment Property and equipment at December 31, 2018 and 2017 consisted of the following: (In thousands) December 31, 2018 December 31, 2017 Leasehold improvements $ 10,404 $ 10,384 Computer equipment and related software 22,200 19,508 Furniture and office equipment 8,053 8,194 Capital projects in process 6,395 1,105 Total property and equipment at cost $ 47,052 $ 39,191 Less: accumulated depreciation (30,711 ) (28,533 ) Total property and equipment, net $ 16,341 $ 10,658

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2018
Goodwill [Abstract]
Goodwill	6 . Goo d w i ll There was no c h g the m d i r n e b 31 2018 or 2017.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2018
Intangible Assets Net Excluding Goodwill [Abstract]
Intangible Assets	7 . Intangible Intangible assets subject to amortization at December 31, 2018 consisted of the following: (In thousands) Gross Carrying Amount Accumulated Amortization Net Acquired technology $ 1,483 $ (1,483 ) — Distributor and provider networks 8,709 (8,709 ) — Total $ 10,192 $ (10,192 ) $ — Intangible assets subject to amortization at December 31, 2017 consisted of the following: (In thousands) Gross Carrying Amount Accumulated Amortization Net Acquired technology $ 1,733 $ (1,733 ) — Distributor and provider networks 8,709 (8,709 ) — Total $ 10,442 $ (10,442 ) $ — As all intangible a j i o a z i n o 0 2 a Intangible a n j i e e m 3 18 0 i a .

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	8 . Income Taxes Income tax expense (benefit) is comprised of the following: Year Ended December 31, (In thousands) 2018 2017 2016 Current taxes: Federal $ 29 $ 771 $ (426 ) State 1,857 373 311 Deferred taxes: Federal 20,136 37,565 18,910 State 5,024 4,844 3,178 Total $ 27,046 $ 43,553 $ 21,973 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table sets forth the significant components of our net deferred tax asset and liability as of December 31, 2018 and 2017: (In thousands) December 31, 2018 December 31, 2017 Deferred tax asset: Accruals and reserves $ 769 $ 1,539 Deferred compensation 496 1,439 Share-based payments 2,111 2,944 Net operating loss carryforwards 9,430 32,122 Capital loss carryforwards 7,620 8,102 Cash Conversion Derivative — 25,821 Tax credits 6,437 6,994 Other assets — 320 26,863 79,281 Valuation allowance (10,457 ) (11,462 ) $ 16,406 $ 67,819 Deferred tax liability: Property and equipment $ (2,600 ) $ (2,104 ) Intangible assets (14,125 ) (14,728 ) Cash Convertible Notes Hedges — (25,821 ) (16,725 ) (42,653 ) Net long-term deferred tax asset (liability) $ (319 ) $ 25,166 In December 2017, we recorded $5.0 million of tax expense necessary to revalue our deferred tax assets and liabilities at the new 21% federal rate as enacted in the Tax Cuts and Jobs Act of 2017 (the "Tax Act"). At December 31, 2018, we provided valuation allowances for $2.4 million of deferred tax assets associated with our international net operating loss carryforwards, $0.5 million of deferred tax assets associated with our state net operating loss carryforwards, and $7.6 million for deferred tax assets related to capital loss carryforwards incurred in the sale of the TPHS business. We recorded a total decrease in our valuation allowance of $1.0 million for the year ended December 31, 2018. Our valuation allowance at December 31, 2018 is $10.5 million. At December 31, 2018, we had international net operating loss carryforwards totaling approximately $8.0 million with an indefinite carryforward period, approximately $5.2 million of federal net operating loss carryforwards, approximately $105.1 million of state net operating loss carryforwards expiring between 2021 and 2037, approximately $30.5 million of capital loss carryforwards expiring in 2021, and approximately $4.6 million of foreign tax credits expiring between 2022 and 2027. Of the federal net operating loss carryforwards, $1.4 million is subject to annual limitation under Internal Revenue Code Section 382 and expires in 2022, if not utilized. The remainder of the federal net operating loss carryforwards expires in 2037. Upon adoption of ASU 2016-09 on January 1, 2017, we recorded a $6.5 million increase in deferred tax assets as a cumulative-effect adjustment to retained earnings. The increase in deferred tax assets related to the previously suspended portion of net operating losses attributable to excess tax deductions from share-based payment awards. In 2017, our undistributed foreign earnings were subject to the mandatory deemed repatriation (“toll charge”) provision included in the Tax Act, and we repatriated these earnings during 2017. Due to the mandatory deemed repatriation, we recorded $2.5 million of tax expense in continuing operations as of the date of enactment. The difference between income tax expense computed using the statutory federal income tax rate and the effective rate is as follows: Year Ended December 31, (In thousands) 2018 2017 2016 Statutory federal income tax $ 26,239 $ 36,674 $ 27,321 State income taxes, less federal income tax benefit 6,261 5,119 3,801 Permanent items 1,496 1,750 954 Change in valuation allowance (1,005 ) — (9,615 ) Share-based compensation (6,378 ) (6,441 ) — Tax Act adjustments — 7,442 — Change in uncertain tax position liability (644 ) — — Prior year tax adjustments (590 ) (544 ) (444 ) Net impact of foreign operations 990 — — State income tax credits 677 (447 ) (44 ) Income tax expense $ 27,046 $ 43,553 $ 21,973 Uncertain Tax Positions During 2018, we recorded a $0.6 million reduction to an unrecognized tax benefit due to the settlement of a tax audit related to state refund claims for tax years 2012 through 2015. As of December 31, 2018, we had no unrecognized tax benefits that would affect our effective tax rate. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. During 2018, 2017, and 2016, there were no interest and penalties related to unrecognized tax benefits recorded as income tax expense. The aggregate changes in the balance of unrecognized tax benefits, exclusive of interest, were as follows: (In thousands) Unrecognized tax benefits at December 31, 2016 $ — Increases based upon tax positions related to prior years 644 Unrecognized tax benefits at December 31, 2017 $ 644 Decreases based upon settlements with taxing authorities (644 ) Unrecognized tax benefits at December 31, 2018 $ — We file income tax returns in the U.S. Federal jurisdiction and in various state and foreign jurisdictions. Tax years remaining subject to examination in the U.S. Federal jurisdiction include 2015 to present.

Debt

Debt	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Debt	9 . Debt The Company's debt, net of unamortized deferred loan costs, consisted of the following at December 31, 2018 and 2017: (In thousands) December 31, 2018 December 31, 2017 Cash Convertible Notes, net of unamortized discount $ — $ 145,861 Delayed draw term loan 25,000 — Revolving credit facility 5,450 — Capital lease obligations and other 196 549 30,646 146,410 Less: deferred loan costs — (451 ) Total debt 30,646 145,959 Less: current portion (57 ) (145,959 ) Long-term debt $ 30,589 $ — Credit Facility On April 21, 2017, we entered into a new Revolving Credit and Term Loan Agreement (the “Credit Agreement”) with a group of lenders. The Credit Agreement replaced the prior Fifth Amended and Restated Revolving Credit and Term Loan Agreement (the “Prior Credit Agreement”). We used the proceeds of the term loan A and cash on hand to repay all of the outstanding indebtedness under the Prior Credit Agreement and to pay transaction costs and expenses. Proceeds of revolving loans and delayed draw term loans may be used to repay outstanding indebtedness (including amounts payable upon or in respect of any conversion of the Cash Convertible Notes discussed below and the repayment of any revolving loans borrowed for such purposes), to finance working capital needs, to finance acquisitions, to finance the repurchase of our common stock, to finance capital expenditures and for other general corporate purposes of the Company and its subsidiaries. As further detailed below under “1.50% Cash Convertible Senior Notes Due 2018”, on July 2, 2018, we borrowed $100.0 million under the delayed draw term loan, which was used to repay the principal amount of the Cash Convertible Notes. No additional amounts may be borrowed under the delayed draw term after July 2, 2018 We are required to repay any outstanding revolving loans in full on April 21, 2022. The term loan A was repaid in full during 2017 and may not be re-borrowed We are required to repay the delayed draw term loan in quarterly principal installments calculated as follows: (1) for each of the first six quarters following the time of borrowing (beginning with the fourth quarter of 2018 and ending with the first quarter of 2020), 1.250% of the aggregate principal amount of the delayed draw term loan funded as of the last day of the immediately preceding quarter; and (2) for each of the remaining quarters prior to maturity on April 21, 2022, 1.875% of the aggregate principal amount of the delayed draw term loan funded as of the last day of the immediately preceding quarter. During the third and fourth quarters of 2018, we paid down a total of $75.0 million on the delayed draw term loan, which satisfied all of the mandatory principal payments described in items 1 and 2 above and further reduced the principal balance due at maturity. No further principal payments are required until maturity. Borrowings under the Credit Agreement generally bear interest at variable rates based on a margin or spread in excess of either (1) the one-month, two-month, three-month or six-month LIBOR rate (or with the approval of affected lenders, the 12-month LIBOR rate), which may not be less than zero, or (2) the greatest of (a) the SunTrust Bank prime lending rate, (b) the federal funds rate plus 0.50%, and (c) one-month LIBOR plus 1.00% (the “Base Rate”), as selected by the Company. The LIBOR margin varies between 1.50% and 2.75%, and the Base Rate margin varies between 0.50% and 1.75%, depending on our net leverage ratio. The Credit Agreement also provides for annual fees ranging between 0.20% and 0.50% of the unused commitments under the revolving credit facility and the delayed draw term loan facility and annual letter of credit fees on the daily outstanding availability under outstanding letters of credit at the applicable LIBOR margin The Credit Agreement contains financial covenants that require us to maintain, as defined, (1) specified maximum ratios or levels of funded debt to EBITDA and (2) a specified minimum ratio or level of fixed charge coverage. The Credit Agreement also contains various other affirmative and negative covenants that are typical for financings of this type. Among other things, they limit repurchases of our common stock and the amount of dividends that we can pay to holders of our common stock. 1.50% Cash Convertible Senior Notes Due 2018 On July 16, 2013, we completed the issuance of $150.0 million aggregate principal amount of cash convertible senior notes due 2018 (the "Cash Convertible Notes"), which bore interest at a rate of 1.50% per year, payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2014. The Cash Convertible Notes matured on July 2, 2018. All of the holders elected to convert their Cash Convertible Notes for settlement on July 2, 2018, and none of the Cash Convertible Notes were repurchased or converted into cash prior to such date The cash conversion feature of the Cash Convertible Notes was a derivative liability (the "Cash Conversion Derivative") that required bifurcation from the Cash Convertible Notes in accordance with FASB ASC Topic 815, "Derivatives and Hedging" ("ASC Topic 815"), and was carried at fair value. The fair value of the Cash Conversion Derivative at the time of issuance of the Cash Convertible Notes was recorded as a debt discount for purposes of accounting for the debt component of the Cash Convertible Notes. The debt discount was amortized over the term of the Cash Convertible Notes using the effective interest method. For the years ended December 31, 2018 and 2017, we recorded $4.1 million and $8.0 million, respectively, of interest expense related to the amortization of the debt discount based upon an effective interest rate of 5.7%. We also recognized interest expense of $1.1 million, $2.3 million, and $2.3 million for the years ended December 31, 2018, 2017 and 2016, respectively, related to the contractual interest rate of 1.50% per year. In connection with the issuance of the Cash Convertible Notes, we entered into privately negotiated convertible note hedge transactions (the "Cash Convertible Notes Hedges"), which were cash-settled and were intended to reduce our exposure to potential cash payments that we would be required to make if holders elected to convert the Cash Convertible Notes at a time when our stock price exceeded the conversion price. The Cash Convertible Notes Hedges were recorded as a derivative asset under ASC Topic 815 and were carried at fair value. See Note 11 for additional information regarding the Cash Convertible Notes Hedges and the Cash Conversion Derivative and their fair values. On July 2, 2018, we repaid the $150.0 million aggregate principal amount of the Cash Convertible Notes using a combination of available cash and proceeds from borrowings under the delayed draw term loan facility of $100.0 million. In addition, on July 2, 2018 we settled the Cash Conversion Derivative of $141.2 million, which was fully funded by payments made by the counterparties for the settlement of the Cash Convertible Notes Hedges. In July 2013, we also sold separate privately negotiated warrants (the "Warrants") initially relating, in the aggregate, to approximately 7.7 million shares of our common stock underlying the Cash Convertible Notes Hedges Since October 1, 2018, the Warrants have been subject to automatic exercise on a pro rata basis each trading day continuing for a period of 160 trading days (i.e., approximately 48,000 warrants are subject to automatic exercise on each trading day). The Warrants are net share settled by our issuing a number of shares of our common stock per Warrant with a value corresponding to the excess of the market price per share of our common stock (as measured on each warrant exercise date under the terms of the Warrants) over the applicable strike price of the Warrants. If such market price per share is less than the applicable strike price of the Warrants on any given exercise date, then the number of warrants subject to automatic exercise on such exercise date are not exercised but instead expire. The Warrants meet the definition of derivatives under the guidance in ASC Topic 815; however, because these instruments have been determined to be indexed to our own stock and meet the criteria for equity classification under ASC Topic 815, the Warrants have been accounted for as an adjustment to our additional paid-in-capital. During the fourth quarter and year ended December 31, 2018, we issued approximately 627,000 shares of common stock related to the automatic exercise of the Warrants. When the market value per share of our common stock exceeds the strike price of the Warrants, the Warrants have a dilutive effect on net income per share, and the "treasury stock" method is used in calculating the dilutive effect on earnings per share. See Note 15 for additional information on such dilutive effect. The following table summarizes the minimum annual principal payments and repayments of the revolving advances under the Credit Agreement for each of the next five years and thereafter: (In thousands) Year ending December 31, 2019 $ — 2020 — 2021 — 2022 30,450 2023 — 2024 and thereafter — Total $ 30,450

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10 . Commitments and Contingencies Weiner, Denham, and Allen Lawsuits On November 6, 2017, United Healthcare issued a press release announcing expansion of its fitness benefits (“United Press Release”), and the market price of the Company's shares of common stock dropped on that same day. In connection with the United Press Release , three lawsuits have been filed against the Company as described below. We are currently not able to predict the probable outcome of these matters or to reasonably estimate a range of potential losses, if any. We intend to vigorously defend ourselves against all three complaints. On November 20, 2017, Eric Weiner, claiming to be a stockholder of the Company, filed a complaint on behalf of stockholders who purchased the Company’s common stock between February 24, 2017 and November 3, 2017 (“Weiner Lawsuit”). The Weiner Lawsuit was filed as a class action in the U.S. District Court for the Middle District of Tennessee, naming as defendants the Company, the Company's chief executive officer, chief financial officer and a former executive who served as both chief accounting officer and interim chief financial officer. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act in making false and misleading statements and omissions related to the United Press Release. The complaint seeks monetary damages on behalf of the purported class. On April 3, 2018, the Court entered an order appointing the Oklahoma Firefighters Pension and Retirement System as lead plaintiff, designated counsel for the lead plaintiff, and established certain deadlines for the case. On June 4, 2018, Plaintiff filed a first amended complaint. On August 3, 2018, the Company filed a motion to dismiss the first amended complaint and a memorandum in support of a motion to dismiss seeking dismissal on grounds that the first amended complaint fails to plead any actionable statement or omission (the “Motion to Dismiss”) . On January 26, 2018, Charles Denham, claiming to be a stockholder of the Company, filed a purported shareholder derivative action, on behalf of the Company, in the U.S. District Court for the Middle District of Tennessee, naming the Company as a nominal defendant and the Company's chief executive officer, chief financial officer, a former executive who served as both chief accounting officer and interim chief financial officer, current directors and a former director of the Company, as defendants (“Denham Lawsuit”). The complaint asserts claims for breach of fiduciary duty, waste, and unjust enrichment, largely tracking allegations in the Weiner Lawsuit. The complaint further alleges that certain defendants engaged in insider trading. The plaintiff seeks monetary damages on behalf of the Company, certain corporate governance and internal procedural reforms, and other equitable relief . On August 24, 2018, Andrew H. Allen, claiming to be a stockholder of the Company, filed a purported shareholder derivative action, on behalf of the Company, in the U.S. District Court for the Middle District of Tennessee, naming the Company as a nominal defendant and the Company’s chief executive officer, chief financial officer, a former executive who served as both chief accounting officer and interim chief financial officer, together with nine current or former directors, as defendants (the “Allen Lawsuit”). The complaint asserts claims for breach of fiduciary duty and violations of the Securities Act of 1933, as amended (the “Securities Act”) and the Exchange Act against all individual defendants, largely tracking allegations in the Weiner Lawsuit and Denham Lawsuit, and breach of fiduciary duty for insider trading against a former executive who served as both chief accounting officer and interim chief financial officer and one of the directors of the Company. The plaintiff seeks to recover damages on behalf of the Company, certain corporate governance and internal procedural reforms, and other equitable relief, including restitution from the two defendants alleged to have engaged in insider trading from all unlawfully obtained profits. On October 15, 2018, the Allen Lawsuit and the Denham Lawsuit were consolidated by stipulation, and the consolidated case was stayed pending entry of an order resolving the Motion to Dismiss filed in the Weiner Lawsuit. Other Additionally, from time to time, we are subject to contractual disputes, claims and legal proceedings that arise from time to time in the ordinary course of our business. Some of the legal proceedings pending against us as of the date of this report are expected to be covered by insurance policies. As these matters are subject to inherent uncertainties, our view of these matters may change in the future.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	11 . Fai Valu We account for certain assets and liabilities at fair value. Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. Fair Value Hierarchy The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1: Quoted prices in active markets for identical assets or liabilities; Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-based valuation techniques in which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs that are supported by little or no market activity and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis We measure certain assets at fair value on a nonrecurring basis in the fourth quarter of the year, including the following: • reporting units measured at fair value as part of a goodwill impairment test; and • indefinite-lived intangible assets measured at fair value for impairment assessment. Each of these assets above is classified as Level 3 within the fair value hierarchy. During the fourth quarter of 2018, we reviewed goodwill for impairment at the reporting unit level (operating segment or one level below an operating segment). We have a single reporting unit. The fair value of a reporting unit is the price that would be received upon a sale of the unit as a whole in an orderly transaction between market participants at the measurement date. We estimated the fair value of the rep o rting unit based on our market capitalization and compared such fair value to the carrying value of the reporting unit. the fair value of the reporting unit exceeded its carrying amount Also during the fourth quarter of 2018, we estimated the fair value of our indefinite-lived intangible asset, a tradename, using a present value technique, which required management's estimate of future revenues attributable to this tradename, estimation of the long-term growth rate and royalty rate for this revenue, and determination of our weighted average cost of capital. Changes in these estimates and assumptions could materially affect the estimate of fair value for the tradename. We determined that the carrying value of the tradename was not impaired based upon the impairment review. Assets and Liabilities Measured at Fair Value on a Recurring Basis As described in Note 9, the Cash Convertible Notes Hedges and Cash Conversion Derivative were settled upon their maturity on July 2, 2018 and therefore had a value of $0 at December 31, 2018. At December 31, 2017, the fair values of the Cash Convertible Notes Hedges and the Cash Conversion Derivative were measured using Level 3 inputs because these instruments were not actively traded. The Cash Convertible Notes Hedges and the Cash Conversion Derivative were designed such that changes in their fair values would offset one another, with minimal impact to the consolidated statements of operations. The following table presents our financial instruments measured at fair value on a recurring basis using unobservable inputs (Level 3): (In thousands) Balance at December 31, 2017 Purchases of Instruments Settlements of Level 3 Instruments Gains (Losses) Included in Earnings Balance at December 31, 2018 Cash Convertible Notes Hedges (Assets) $ 134,079 $ — $ (141,246 ) $ 7,167 $ — Cash Conversion Derivative (Liabilities) (134,079 ) — 141,246 (7,167 ) — The gains and losses included in earnings noted above represent the change in the fair value of these financial instruments and were recorded in the consolidated statements of operations as selling, general and administrative expenses. Fair Value of Other Financial Instruments In addition to the Cash Convertible Notes Hedges and the Cash Conversion Derivative, the estimated fair values of which are disclosed above, the estimated fair value of each class of financial instruments at December 31, 2018 was as follows: Cash and cash equivalents – The carrying amount of $1.9 million approximates fair value because of the short maturity of those instruments (less than three months). Debt – The estimated fair value of outstanding borrowings under the Credit Agreement, which includes a revolving credit facility and a term loan facility (see Note 9), are determined based on the fair value hierarchy as discussed above. The revolving credit facility and the term loan facility are not actively traded and therefore are classified as Level 2 valuations based on the market for similar instruments. The estimated fair value is based on the maximum of the prices set by the issuing bank given current market conditions and is not necessarily indicative of the amount we could realize in a current market exchange. The estimated fair value and carrying amount of outstanding borrowings under the Credit Agreement at December 31, 2018 were $30.1 million and $30.5 million, respectively.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Dec. 31, 2018
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	1 2 . Deri v v n n a n v As of December 31, 2018, we did not hold any derivative instruments or hedges. Historically, we used derivative instruments to manage risks related to interest (through December 30, 2016), the Cash Convertible Notes (which matured and were repaid on July 2, 2018), and, prior to the sale of the TPHS business, foreign currencies. We account for derivatives in accordance with ASC Topic 815, which establishes accounting and reporting standards requiring that certain derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivative's fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. We do not execute transactions or hold derivative financial instruments for trading or other purposes Der i vat i ve Instru m ents Not D e sig n ated a s H e dgi n g Instru m ents The a o i i e H g in the con s olidated statements of com p r e he n s i ve income (l o ss). T hes e derivativ e instrumen t s di d no t hav e a materia l im p a c t o n our co n sol i dated statemen t s of com p re h e n s i v e income (l o ss) for the y e ars e nd e d D e cem b er 3 1, 2018 a n d 20 17 . The Cash i i i s o i e e e e e i were a h e e e p u e a y l e e l e a e o o p e v i p a o g were u d v a i The gains and losses resulting from a change in fair values of the Cash Conversion Derivative and the Cash Convertible Notes Hedges are reported in the consolidated statements of comprehensive income (loss). Year Ended December 31, (In thousands) 2018 2017 Statements of Comprehensive Income (Loss) Classification Cash Convertible Notes Hedges: Net unrealized gain $ 7,167 $ 85,718 Selling, general and administrative expense Cash Conversion Derivative: Net unrealized loss $ (7,167 ) $ (85,718 ) Selling, general and administrative expense The estimated gross fair values of derivative instruments at December 31, 2018 and December 31, 2017 were as follows: (In thousands) December 2018 December 2017 Assets: Derivatives not designated as hedging instruments: Cash convertible notes hedges, current $ — $ 134,079 Liabilities: Derivatives not designated as hedging instruments: Cash conversion derivative, current $ — $ 134,079 See Note 11 for more information on fair value measurements.

Leases

Leases	12 Months Ended
	Dec. 31, 2018
Leases [Abstract]
Leases	1 3 . Leases We maintain operating lease agreements principally for our office spaces. We lease approximately 264,000 square feet of office space for our corporate headquarters in Franklin, Tennessee pursuant to an agreement that commenced in March 2008 and expires in February 2023. Approximately 221,000 square feet of such space is subleased to other tenants. We also lease approximately 92,000 square feet of office space in Chandler, Arizona, and approximately 6,000 square feet of office space in Ashburn, Virginia. The Chandler, Arizona lease began in April 2009 and expires in April 2020. Our corporate office lease agreement in Tennessee contains escalation clauses and provides for two renewal options of five years each at then prevailing market rates. The base rent for the initial 15-year term ranges from $4.3 million to $6.6 million per year over the term of the lease. The landlord provided a tenant improvement allowance equal to approximately $10.7 million. We record leasehold improvement incentives as deferred rent and amortize them as reductions to rent expense over the lease term. Most of our operating leases include escalation clauses, some of which are fixed amounts, and some of which reflect changes in price indices. We recognize rent expense on a straight-line basis over the lease term. Certain operating leases contain renewal options to extend the lease for additional periods. For the years ended December 31, 2018, 2017, and 2016, rent expense under lease agreements, net of sublease income, was approximately $2.7 million, $2.5 million, and $4.2 million, respectively. Our capital lease obligations are included in long-term debt and the current portion of long-term debt. The following table summarizes our future minimum lease payments, net of total cash receipts from subleases of $23.7 million, under all non-cancelable operating leases for each of the next five years and thereafter. As of December 31, 2018, future minimum lease payments under capital leases were not material. (In thousands) Operating Year ending December 31, Leases 2019 $ 4,022 2020 2,040 2021 910 2022 827 2023 136 2024 and thereafter — Total minimum lease payments $ 7,935

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	1 4 . Share-Based Compensation We currently have three types of share-based awards outstanding to our employees and directors: stock options, restricted stock units, and market stock units. We believe that our share-based awards align the interests of our employees and directors with those of our stockholders. We grant options under these plans at fair value on the date of grant. The options generally vest over three or four years based on service conditions and expire ten years from the date of grant. Restricted stock units generally vest over three or four years. Market stock units granted during 2016 and 2015 have a multi-year performance period ending in 2019 and 2018, respectively, and vest at the end of the three-year performance period based on total shareholder return. We recognize share-based compensation expense for options and restricted stock units on a straight-line basis over the vesting period. We account for forfeitures as they occur. Following are certain amounts recognized in the consolidated statements of operations for share-based compensation arrangements for the years ended December 31, 2018, 2017, and 2016. We did not capitalize any share-based compensation costs during these periods. Year Ended December December 31, December 31, (In millions) 2018 2017 2016 Total share-based compensation $ 6.1 $ 6.7 $ 17.5 Share-based compensation included in cost of services 2.3 2.2 1.2 Share-based compensation included in selling, general and administrative expenses 3.8 4.4 5.9 Share-based compensation included in restructuring and related charges — 0.1 0.3 Share-based compensation included in discontinued operations (1) — — 10.1 Total income tax benefit recognized 1.6 2.6 2.9 (1) Includes the acceleration of vesting in 2016 of all unvested stock options, market stock units and restricted stock units held by two former senior executives as of the Closing who had accepted employment with Sharecare. In connection with the sale of the TPHS business, we modified approximately 92,000 options, 396,000 restricted stock units, and 75,000 market stock units by accelerating the vesting dates to July 31, 2016 (the date on which the sale of the TPHS business was consummated) for approximately 100 employees of the TPHS business. This resulted in share-based compensation expense of $7.4 million, all of which is included in discontinued operations for the year ended December 31, 2016. As of December 31, 2018, there was $4.9 million of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the stock incentive plans. That cost is expected to be recognized over a weighted average period of 1.2 years. Stock Options We use a lattice-based binomial option valuation model ("lattice binomial model") to estimate the fair values of stock options. We base expected volatility on historical volatility due to the low volume of traded options on our stock. The expected term of options granted is derived from the output of the lattice binomial model and represents the period of time that options granted are expected to be outstanding. We used historical data to estimate expected option exercise and post-vesting employment termination behavior within the lattice binomial model. The following table sets forth the weighted average grant-date fair values of options and the weighted average assumptions we used to develop the fair value estimates for the year ended December 31, 2018. There were no stock options granted during fiscal 2017 or 2016. Year Ended December 2018 Weighted average grant-date fair value of options per share $ 20.21 Assumptions: Expected volatility 56.2 % Expected dividends — Expected term (in years) 6.7 Risk-free rate 2.8 % A summary of options as of December 31, 2018 and the activity during the year then ended is presented below: Options Shares (In Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding at January 1, 2018 507 $ 12.98 Granted 86 37.94 Exercised (156 ) 12.28 Forfeited (6 ) 39.45 Expired — — Outstanding at December 31, 2018 431 $ 17.83 4.4 $ 4,045 Exercisable at December 31, 2018 351 $ 13.29 3.3 $ 4,045 The total intrinsic value, which represents the difference between the market price of the underlying common stock and the option's exercise price, of options exercised during the years ended December 31, 2018, 2017, and 2016 was $3.9 million, $10.5 million, and $10.2 million, respectively. Cash received from option exercises under all share-based payment arrangements during 2018 was $1.9 million. The actual tax benefit realized during 2018 for the tax deductions from option exercise totaled $1.0 million. We issue new shares of common stock upon exercise of stock options or vesting of restricted stock units and market stock units. Nonvested Shares The fair value of restricted stock units is determined based on the closing bid price of the Company's common stock on the grant date. The weighted average grant-date fair value of restricted stock units granted during the years ended December 31, 2018, 2017, and 2016 was $38.12, $32.06, and $12.37, respectively. The fair value of market stock units is determined based on the closing bid price of the Company's common stock on the grant date, except that the Monte Carlo simulation valuation model is used to determine the fair value of market stock units with a market condition. The weighted average grant-date fair value of all market stock units granted during fiscal 2016 was $10.67. No market stock units were granted during 2018 or 2017. The two tables below set forth a summary of our nonvested shares as of December 31, 2018 as well as activity during the year then ended. The total grant-date fair value of shares vested during the years ended December 31, 2018, 2017, and 2016 was $7.6 million, $5.7 million, and $13.9 million, respectively. The following table shows a summary of our restricted stock units as of December 31, 2018 as well as activity during the year then ended: Restricted Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2018 572 $ 17.60 Granted 74 38.12 Vested (339 ) 16.26 Forfeited (36 ) 24.07 Nonvested at December 31, 2018 271 $ 24.07 The following table shows a summary of our market stock units as of December 31, 2018 as well as activity during the year then ended: Market Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2018 373 $ 9.01 Granted — — Shares adjustment for above-target performance (1) 185 6.80 Vested (474 ) 6.80 Forfeited (39 ) 14.76 Nonvested at December 31, 2018 45 $ 18.25 (1) Represents the number of shares earned in excess of target for certain market stock units that vested during the year. These awards were reported at the target number of shares when granted.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	1 5 . Earning (L o ss Pe Sha r The i e o a u o n i o i d g o s e o ea r e e e 3 17 (In thousands except per share data) Year Ended December 31, Numerator: 2018 2017 2016 Income from continuing operations attributable to Tivity Health, Inc. - numerator for earnings per share $ 97,902 $ 61,230 $ 56,091 Net income (loss) from discontinued operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share 901 2,485 (185,202 ) Net income (loss) attributable to Tivity Health, Inc. - numerator for earnings (loss) per share $ 98,803 $ 63,715 $ (129,111 ) Denominator: Shares used for basic income (loss) per share 40,078 39,357 36,999 Effect of dilutive stock options and restricted stock units outstanding: Non-qualified stock options 264 436 344 Restricted stock units 299 549 538 Warrants related to Cash Convertible Notes 2,013 1,709 — Market stock units 419 496 194 Shares used for diluted income (loss) per share 43,073 42,547 38,075 Earnings (loss) per share attributable to Tivity Health, Inc. - basic: Continuing operations $ 2.44 $ 1.56 $ 1.52 Discontinued operations $ 0.02 $ 0.06 $ (5.01 ) Net income (loss) (1) $ 2.47 $ 1.62 $ (3.49 ) Earnings (loss) per share attributable to Tivity Health, Inc. - diluted: Continuing operations $ 2.27 $ 1.44 $ 1.47 Discontinued operations $ 0.02 $ 0.06 $ (4.86 ) Net earnings (loss) $ 2.29 $ 1.50 $ (3.39 ) Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive: Non-qualified stock options 56 4 708 Restricted stock units 36 12 333 Warrants related to Cash Convertible Notes — — 7,707 (1) Figures may not add due to rounding. Market stock units outstanding are considered contingently issuable shares, and certain of these market stock units were excluded from the calculations of diluted earnings per share for all periods presented because the performance criteria had not been met as of the end of the reporting periods.

Accumulated OCI

Accumulated OCI	12 Months Ended
	Dec. 31, 2018
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Accumulated OCI	1 6 . Accumulated OCI There were no changes in accumulated other comprehensive income (loss) (“OCI”) for the year ended December 31, 2018. The following table summarizes the changes in accumulated OCI, net of tax, for the year ended December 31, 2017: (In thousands) Foreign Currency Translation Adjustments Accumulated OCI, net of tax, as of January 1, 2017 $ (4,502 ) Other comprehensive income before reclassifications, net of tax of $225 1,458 Amounts reclassified from accumulated OCI, net of tax of $0 3,044 (1) Accumulated OCI, net of tax, as of December 31, 2017 $ — (1) This amount was reclassified out of accumulated OCI to gain (loss) on discontinued operations during the year ended December 31, 2017 and had a tax effect of $0. There were no reclassifications out of accumulated OCI to income from continuing operations for the years ended December 31, 2018 and 2017.

Segment Disclosures and Concent

Segment Disclosures and Concentrations of Risk	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Segment Disclosures and Concentrations of Risk	1 7 . Segment Disclosures and Concentrations of Risk During 2018 and 2017, we had one operating and reportable segment. Therefore, all required segment information can be found in the consolidated financial statements. Long-lived assets and revenue from external customers attributable to our operations in the United States accounted for 100% of our consolidated long-lived assets and revenues as of and for the years ended December 31, 2018 and 2017. During 2018, we had three customers that each accounted for 10% or more of our revenues and individually comprised approximately 20.0%, 14.6%, and 10.0%, respectively, of our revenues for 2018. No other customer accounted for 10% or more of our revenues in 2018. In addition, at December 31, 2018, we had two customers that each accounted for 10% of more of our accounts receivable, net and individually comprised approximately 26% and 13%, respectively, of our accounts receivable, net at December 31, 2018. During 2017, we had two customers that each accounted for 10% or more of our revenues and individually comprised approximately 20.3% and 17.4%, respectively, of our revenues for 2017. No other customer accounted for 10% or more of our revenues in 2017. In addition, at December 31, 2017, we had two customers that each accounted for 10% of more of our accounts receivable, net and individually comprised approximately 31% and 11%, respectively, of our accounts receivable, net at December 31, 2017.

Pending Acquisition of Nutrisys

Pending Acquisition of Nutrisystem	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Pending Acquisition of Nutrisystem	1 8 . Pending Acquisition of Nutrisystem On December 9, 2018, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Nutrisystem, Inc. (“Nutrisystem”) and Sweet Acquisition, Inc., a wholly-owned subsidiary of Tivity Health (“Merger Sub”). The Merger Agreement provides, among other things, that, upon the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Nutrisystem, with Nutrisystem surviving as a wholly-owned subsidiary of Tivity Health (the “Merger”). Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of common stock, par value $.001 per share, of Nutrisystem issued and outstanding immediately prior to the Effective Time (other than shares as to which appraisal rights have been properly exercised and certain other excluded shares) will be converted into the right to receive (i) $38.75 in cash, without interest, and (ii) 0.2141 shares of common stock of Tivity Health, with cash payable in lieu of fractional shares of common stock of Tivity Health. In connection with the Merger Agreement, on December 9, 2018, Tivity Health entered into a debt commitment letter and corresponding fee letters (the “Debt Commitment Letter”) with Credit Suisse AG (“CS”), and Credit Suisse Loan Funding LLC (“CSLF”). On December 21, 2018, December 26, 2018, December 27, 2018, December 31, 2018 and January 4, 2019, the Debt Commitment Letter was amended to add SunTrust Robinson Humphrey, Inc. (“STRH”), SunTrust Bank (“SunTrust”), Citigroup Global Markets Inc., on behalf of itself and Citibank, N.A., Citicorp USA, Inc., Citicorp North America, Inc. and affiliates thereof, (“CGMI”), Citizens Bank, N.A. (“Citizens”), Fifth Third Bank (“Fifth Third”), Regions Bank (“Regions Bank”), Regions Capital Markets, a division of Regions Bank, (“Regions Capital Markets”), and Goldman Sachs Bank USA, together with its affiliates, including Goldman Sachs Lending Partners LLC, (“GS,” and collectively with CS, CSLF, STRH, SunTrust, CGMI, Citizens, Fifth Third, Regions Bank, Regions Capital Markets and each of their respective affiliates, the “Commitment Parties”), as Commitment Parties under the Debt Commitment Letter and to adjust correspondingly each Commitment Party’s commitment with respect to the financing contemplated thereby. Under the Debt Commitment Letter, among other things, CSLF, STRH, CGMI, Citizens, Fifth Third, Regions Capital Markets and GS have committed to arrange, and CS, SunTrust, CGMI, Citizens, Fifth Third, Regions Bank and GS have committed to provide, subject to terms and conditions set forth in the Debt Commitment Letter, a senior secured term loan facility in an aggregate principal amount of $1,210,000,000 and a senior secured revolving credit facility in an aggregate principal amount of $125,000,000 (collectively, the “Financing”). The Financing will be secured by a first priority security interest and lien on substantially all of the assets of Tivity Health and its wholly-owned material domestic subsidiaries. The Commitment Parties’ commitments pursuant to the Debt Commitment Letter are subject to various conditions, including consummation of the Merger in accordance with the Merger Agreement; the negotiation and execution of definitive documentation consistent with the Debt Commitment Letter; delivery of certain audited, unaudited and pro forma financial statements; the absence of a material adverse effect on Nutrisystem after December 9, 2018; the accuracy of representations and warranties of Nutrisystem in the Merger Agreement and specified representations and warranties of Tivity Health to be set forth in the definitive loan documents; the repayment of all outstanding indebtedness and other obligations of Tivity Health and Nutrisystem under their existing credit facilities; and other customary closing conditions.

Quarterly Financial Information

Quarterly Financial Information (unaudited)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (unaudited)	1 9 . Qua r r na d (In thousands, except per share data) Year Ended December 31, 2018 First Second Third Fourth (1) Revenues $ 149,930 $ 151,865 $ 151,467 $ 153,037 Gross margin 40,678 41,848 43,349 43,601 Income before income taxes 28,493 30,352 34,386 31,717 Income from continuing operations 21,336 22,683 25,357 28,526 Income from discontinued operations, net of income tax — 901 — — Net income 21,336 23,584 25,357 28,526 Earnings per share – basic: Continuing operations (2) $ 0.54 $ 0.57 $ 0.63 $ 0.70 Discontinued operations (2) $ — $ 0.02 $ — $ — Net income (2) (3) $ 0.54 $ 0.59 $ 0.63 $ 0.70 Earnings per share – diluted: Continuing operations (2) $ 0.49 $ 0.52 $ 0.59 $ 0.67 Discontinued operations (2) $ — $ 0.02 $ — $ — Net income (2) (3) $ 0.49 $ 0.54 $ 0.59 $ 0.67 (In thousands, except per share data) Year Ended December 31, 2017 First Second Third Fourth (4) Revenues $ 140,970 $ 138,914 $ 137,703 $ 139,354 Gross margin 37,914 39,195 42,465 38,970 Income before income taxes 24,852 26,800 30,289 22,843 Income from continuing operations 15,481 17,240 19,886 8,624 Income (loss) from discontinued operations, net of income tax (220 ) (3,673 ) 6,519 (141 ) Net income 15,261 13,567 26,405 8,483 Earnings (loss) per share – basic: Continuing operations (2) $ 0.40 $ 0.44 $ 0.50 $ 0.22 Discontinued operations (2) $ (0.01 ) $ (0.09 ) $ 0.17 $ (0.00 ) Net income (2) (3) $ 0.39 $ 0.35 $ 0.67 $ 0.21 Earnings (loss) per share – diluted: Continuing operations (2) $ 0.38 $ 0.41 $ 0.46 $ 0.20 Discontinued operations (2) $ (0.01 ) $ (0.09 ) $ 0.15 $ 0.00 Net income (2) (3) $ 0.38 $ 0.32 $ 0.61 $ 0.20 (1) (2) We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share. (3 ) Figures may not add due to rounding. (4 ) The Tax Act was signed into law during the fourth quarter of 2017, and we incurred a non-cash charge of $7.4 million during the quarter related to both the re-measurement of our deferred tax assets to the lower tax rate

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	a. Principles of Consolidation – See discussion above regarding the TPHS business, including a non-controlling interest. We have eliminated all intercompany profits, transactions, and balances.
Cash and Cash Equivalents	b. Cash and Cash Equivalents - Cash and cash equivalents primarily include cash on deposit.
Accounts Receivable, net	c. Accounts Receivable, net - Accounts receivable includes billed and unbilled amounts. Billed receivables represent fees that are contractually due for services performed, net of allowances for doubtful accounts (reflected as selling, general and administrative expenses). Allowances for doubtful accounts were $0 at December 31, 2018 and 2017. Historically, we have experienced minimal instances of customer non-payment and therefore consider our accounts receivable to be collectible; however, we provide reserves, when appropriate, for doubtful accounts on a specific identification basis. Unbilled receivables primarily represent fees recognized for monthly member utilization of fitness facilities under our SilverSneakers fitness solution, billed one month in arrears.
Property and Equipment	d. Property and Equipment - Property and equipment is carried at cost and includes expenditures that increase value or extend useful lives. We recognize depreciation using the straight-line method over useful lives of three to seven years for computer software and hardware and four to seven years for furniture and other office equipment. Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the life of the lease, which ranges from two to fifteen years. Depreciation expense for the years ended December 31, 2018, 2017, and 2016 was $4.7 million, $3.4 million, and $3.6 million, respectively, including depreciation of assets recorded under capital leases.
Other Assets	e. Other Assets - Other assets consist primarily of shares of common stock of Sharecare (see Note 4), which are accounted for as a cost method investment, and customer incentives. We have elected
Intangible Assets	f. Intangible Assets - Intangible assets subject to amortization include customer contracts, acquired technology, and distributor and provider networks, which we amortized on a straight-line basis over estimated useful lives ranging from three to ten years. All intangible assets subject to amortization were fully amortized at December 31, 2018 and 2017. We assess the potential impairment of intangible assets subject to amortization whenever events or changes in circumstances indicate that the carrying values may not be recoverable. If we determine that the carrying value of identifiable intangible assets may not be recoverable, we calculate any impairment using an estimate of the asset's fair value based on the estimated price that would be received to sell the asset in an orderly transaction between market participants. Intangible assets not subject to amortization at December 31, 2018 and 2017 consist of a trade name of $29.0 million. We review intangible assets not subject to amortization on an annual basis or more frequently whenever events or circumstances indicate that the assets might be impaired. See Note 7 for further information on intangible assets.
Goodwill	g. Goodwill - We recognize goodwill for the excess of the purchase price over the fair value of tangible and identifiable intangible net assets of businesses that we acquire. We review goodwill for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (during the fourth quarter of the fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. We have a single reporting unit. As part of the impairment evaluation, we may elect to perform a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If w e elect not to perform a qualitat i ve assessment or we determine that it is more l i kely than not that the fair value of the rep o rting unit is less than its c a rryi n g value, we perform a quantitative review as descr i bed be l ow. Dur i ua d o If we determine that the carrying value of goodwill is impaired, we calculate any impairment using a fair-value based goodwill impairment test as required by U.S. GAAP. The fair value of a reporting unit is the price that would be received upon a sale of the unit as a whole in an orderly transaction between market participants at the measurement date.
Accounts Payable	h. Accounts Payable - Accounts payable consists of short-term trade obligations and includes cash overdrafts attributable to disbursements not yet cleared by the bank.
Accrued Liabilities	i. Accrued Liabilities – Accrued liabilities primarily include amounts owed for estimated member visits to network locations (which actual visit data is typically received approximately one month in arrears)
Income Taxes	j. Income Taxes - We file a consolidated federal income tax return that includes all of our wholly-owned subsidiaries. U.S. GAAP generally require that we record deferred income taxes for the tax effect of differences between the book and tax bases of our assets and liabilities. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are expected to be realized. When we determine that it is more likely than not that we will be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset is made and reflected in income.
Revenue Recognition	k. Revenue Recognition - On January 1, 2018, we adopted Accounting Standards Update (“ASU”) No. 2014-09 (as discussed under “Recent Relevant Accounting Standards” below) using the modified retrospective transition method applied to contracts that were not completed as of January 1, 2018. See Note 3 for a further discussion of revenue recognition.
Earnings (Loss) Per Share	l. Earnings (Loss) Per Share – We calculate basic earnings (loss) per share using weighted average common shares outstanding during the period. We calculate diluted earnings (loss) per share using weighted average common shares outstanding during the period plus the effect of all dilutive potential common shares outstanding during the period unless the impact would be anti-dilutive. See Note 15 for a reconciliation of basic and diluted earnings (loss) per share.
Share-Based Compensation	m. Share-Based Compensation – We recognize all share-based payments to employees in the consolidated statements of operations over the required vesting period based on estimated fair values at the date of grant. See Note 14 for further information on share-based compensation.
Management Estimates	n. Management Estimates – In preparing our consolidated financial statements in conformity with U.S. GAAP, management must make estimates and assumptions that affect: (1) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and (2) the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation (Policies

Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Recent Relevant Accounting Standards	On January 1, 2018, we adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” (“ASC Topic 606”) using the modified retrospective method, pursuant to which we applied ASC Topic 606 to (i) all new contracts entered into after January 1, 2018 and (ii) contracts that were not completed as of January 1, 2018. In accordance with this approach, our results for periods prior to January 1, 2018 were not revised and continue to be reported in accordance with our historical accounting under ASC Topic 605, “Revenue Recognition.” For contracts that were modified prior to January 1, 2018, we have not retrospectively restated the contract for those modifications in accordance with the contract modification guidance in ASC 606-10-25-12 and ASC 606-10-25-13 but instead, using the practical expedient available under ASC 606-10-65-1(f)(4), have reflected the aggregate effect of all modifications when identifying the satisfied and unsatisfied performance obligations, determining the transaction price, and allocating the transaction price. The cumulative impact of our adoption of ASC Topic 606 was not material to record as of January 1, 2018, and there was no material impact on our consolidated income statement, balance sheet, or cash flows. For example, we do not have any material contract assets or contract liabilities as defined under ASC Topic 606. In addition, the incremental costs of obtaining a contract with a customer (for example, sales commissions) that would have been recognized as an asset on January 1, 2018 or on December 31, 2018 were not material to record. See Note 3 for a further discussion of revenue recognition. On January 1, 2018, we adopted ASU No. 2016-15, “Statement of Cash Flows” (Topic 230) (“ASU 2016-15”). ASU 2016-15 addresses how certain cash receipts and cash payments are presented and classified in the statement of cash flows and is to be applied using a retrospective approach. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures and did not result in a reclassification to items in prior periods. On January 1, 2018, we adopted ASU No. 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”), which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 is to be applied prospectively to awards modified on or after January 1, 2018. The adoption of this standard did not have an impact on our consolidated financial statements and related disclosures. In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, “Leases” (“ASU 2016-02” or “ASC 842”), which requires that lessees recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position, and was effective for us on January 1, 2019. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. ASC 842 originally required entities to use a modified retrospective transition method in which companies would initially apply ASC 842 and recognize an adjustment for the effects of the transition as of the beginning of the earliest comparative period presented (January 1, 2017 for the Company). In July 2018, the FASB issued ASU No. 2018-11, “Leases (Topic 842): Targeted Improvements”, which amends ASC 842 to allow entities to change the date of initial application to the beginning of the period of adoption (January 1, 2019 for the Company), with no requirement to recast comparative periods. We adopted ASC 842 as of January 1, 2019 and are electing to recognize the cumulative effect of initially applying the standard as an adjustment to beginning retained earnings as of January 1, 2019. The significant majority of our leases are classified as operating leases. Although we are still finalizing our analysis, we expect the new lease standard to have a material effect on our consolidated financial statements. The most significant effects relate to our recognition of new right-of-use assets and lease liabilities. We do not expect ASC 842 to have a material impact on net income or the statement of cash flows. In addition, we elected the following practical expedients available under ASC 842: (1) the package of practical expedients whereby we are not required to reassess upon adoption of ASC 842 (a) whether a contract is or contains a lease, (b) lease classification, and (c) initial direct costs (ASC 842-10-65-1(f)); and (2) the short-term lease measurement and recognition exemption (ASC 842-20-25-2). ASC 842 will also require significant new disclosures about leasing activity . In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other” (“ASU 2017-04”), which simplifies the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. ASU 2017-04 is effective for annual and interim impairment tests in fiscal years beginning after December 15, 2019 and is required to be applied prospectively. Early adoption is allowed for annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not anticipate that adopting this standard will have an impact on our consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC 820. ASU 2018-13 is effective for fiscal years beginning on or after December 15, 2019, including interim periods therein, and is generally required to be applied retrospectively, except for certain components that are to be applied prospectively. Early adoption is permitted for any eliminated or modified disclosures. We do not anticipate that adopting this standard will have a material impact on our disclosures. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires companies to measure credit losses for financial assets held at the reporting date utilizing a methodology that reflects current expected credit losses over the lifetime of such assets. ASU 2016-13 is effective for the Company on January 1, 2020 and is generally required to be applied using the modified retrospective approach, with limited exceptions for specific instruments. We do not anticipate that adopting this standard will have an impact on our consolidated financial statements and related disclosures.

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2018
Discontinued Operations And Disposal Groups [Abstract]
Financial Results Included in Losses from Discontinued Operations	The following table presents financial results of the TPHS business included in “income (loss) from discontinued operations" for the years ended December 31, 2018, 2017, and 2016. Year Ended December 31, (In thousands) 2018 2017 2016 Revenues $ — $ — $ 151,780 Cost of services 30 427 173,302 Selling, general & administrative expenses 48 349 18,594 Depreciation and amortization — — 27,207 Restructuring and related charges — — 8,626 Equity in income from joint ventures — 98 243 Pretax loss on discontinued operations (78 ) (678 ) (75,706 ) Pretax loss on release of cumulative translation adjustment (1) — (3,044 ) — Pretax gain (loss) on sale of MeYou Health business (2) 1,416 — (4,826 ) Pretax income (loss) on sale of TPHS business (112 ) 4,733 (202,095 ) Total pretax income (loss) on discontinued operations 1,226 1,011 (282,627 ) Income tax expense (benefit) 325 (1,474 ) (3) (97,921 ) Income (loss) from discontinued operations, net of income tax $ 901 $ 2,485 $ (184,706 ) (1) During the second quarter of 2017, we substantially liquidated foreign entities that were part of our TPHS business, resulting in a release of the cumulative translation adjustment of $3.0 million into loss from discontinued operations. (2) Includes $1.4 million received during the three months ended June 30, 2018 from a release of escrow funds related to the sale of MeYou Health, LLC in June 2016. ( 3 ) Income tax benefit for the year ended December 31, 2017 includes the effect of a change in the estimate of net U.S. tax incurred in 2016 on foreign activity classified as discontinued operations.
Depreciation, Amortization and Significant Operating and Investing Non-cash Items of the Discontinued Operations	The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows: Year Ended December 31, (In thousands) 2018 2017 2016 Depreciation and amortization $ — $ — $ 27,207 Capital expenditures — — 10,258 Share-based compensation — — 10,144

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment at December 31, 2018 and 2017 consisted of the following: (In thousands) December 31, 2018 December 31, 2017 Leasehold improvements $ 10,404 $ 10,384 Computer equipment and related software 22,200 19,508 Furniture and office equipment 8,053 8,194 Capital projects in process 6,395 1,105 Total property and equipment at cost $ 47,052 $ 39,191 Less: accumulated depreciation (30,711 ) (28,533 ) Total property and equipment, net $ 16,341 $ 10,658

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Intangible Assets Net Excluding Goodwill [Abstract]
Intangible Assets Subject to Amortization	Intangible assets subject to amortization at December 31, 2018 consisted of the following: (In thousands) Gross Carrying Amount Accumulated Amortization Net Acquired technology $ 1,483 $ (1,483 ) — Distributor and provider networks 8,709 (8,709 ) — Total $ 10,192 $ (10,192 ) $ — Intangible assets subject to amortization at December 31, 2017 consisted of the following: (In thousands) Gross Carrying Amount Accumulated Amortization Net Acquired technology $ 1,733 $ (1,733 ) — Distributor and provider networks 8,709 (8,709 ) — Total $ 10,442 $ (10,442 ) $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Components of Income Tax Expense (Benefit)	Income tax expense (benefit) is comprised of the following: Year Ended December 31, (In thousands) 2018 2017 2016 Current taxes: Federal $ 29 $ 771 $ (426 ) State 1,857 373 311 Deferred taxes: Federal 20,136 37,565 18,910 State 5,024 4,844 3,178 Total $ 27,046 $ 43,553 $ 21,973
Significant Components of Net Deferred Tax Asset and Liability	The following table sets forth the significant components of our net deferred tax asset and liability as of December 31, 2018 and 2017: (In thousands) December 31, 2018 December 31, 2017 Deferred tax asset: Accruals and reserves $ 769 $ 1,539 Deferred compensation 496 1,439 Share-based payments 2,111 2,944 Net operating loss carryforwards 9,430 32,122 Capital loss carryforwards 7,620 8,102 Cash Conversion Derivative — 25,821 Tax credits 6,437 6,994 Other assets — 320 26,863 79,281 Valuation allowance (10,457 ) (11,462 ) $ 16,406 $ 67,819 Deferred tax liability: Property and equipment $ (2,600 ) $ (2,104 ) Intangible assets (14,125 ) (14,728 ) Cash Convertible Notes Hedges — (25,821 ) (16,725 ) (42,653 ) Net long-term deferred tax asset (liability) $ (319 ) $ 25,166
Difference between Income Tax Expense Computed using Statutory Federal Income Tax Rate and effective rate	The difference between income tax expense computed using the statutory federal income tax rate and the effective rate is as follows: Year Ended December 31, (In thousands) 2018 2017 2016 Statutory federal income tax $ 26,239 $ 36,674 $ 27,321 State income taxes, less federal income tax benefit 6,261 5,119 3,801 Permanent items 1,496 1,750 954 Change in valuation allowance (1,005 ) — (9,615 ) Share-based compensation (6,378 ) (6,441 ) — Tax Act adjustments — 7,442 — Change in uncertain tax position liability (644 ) — — Prior year tax adjustments (590 ) (544 ) (444 ) Net impact of foreign operations 990 — — State income tax credits 677 (447 ) (44 ) Income tax expense $ 27,046 $ 43,553 $ 21,973
Changes in Unrecognized Tax Benefits	The aggregate changes in the balance of unrecognized tax benefits, exclusive of interest, were as follows: (In thousands) Unrecognized tax benefits at December 31, 2016 $ — Increases based upon tax positions related to prior years 644 Unrecognized tax benefits at December 31, 2017 $ 644 Decreases based upon settlements with taxing authorities (644 ) Unrecognized tax benefits at December 31, 2018 $ —

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Summary of Debt, Net of Unamortized Deferred Loan Costs	The Company's debt, net of unamortized deferred loan costs, consisted of the following at December 31, 2018 and 2017: (In thousands) December 31, 2018 December 31, 2017 Cash Convertible Notes, net of unamortized discount $ — $ 145,861 Delayed draw term loan 25,000 — Revolving credit facility 5,450 — Capital lease obligations and other 196 549 30,646 146,410 Less: deferred loan costs — (451 ) Total debt 30,646 145,959 Less: current portion (57 ) (145,959 ) Long-term debt $ 30,589 $ —
Minimum Annual Principal Payments and Repayments of the Revolving Advances	The following table summarizes the minimum annual principal payments and repayments of the revolving advances under the Credit Agreement for each of the next five years and thereafter: (In thousands) Year ending December 31, 2019 $ — 2020 — 2021 — 2022 30,450 2023 — 2024 and thereafter — Total $ 30,450

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Financial Instruments Measured at Fair Value on Recurring Basis Using Unobservable Inputs	The following table presents our financial instruments measured at fair value on a recurring basis using unobservable inputs (Level 3): (In thousands) Balance at December 31, 2017 Purchases of Instruments Settlements of Level 3 Instruments Gains (Losses) Included in Earnings Balance at December 31, 2018 Cash Convertible Notes Hedges (Assets) $ 134,079 $ — $ (141,246 ) $ 7,167 $ — Cash Conversion Derivative (Liabilities) (134,079 ) — 141,246 (7,167 ) —

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Dec. 31, 2018
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Gains and Losses Resulting from Change in Fair Values of Derivatives	The gains and losses resulting from a change in fair values of the Cash Conversion Derivative and the Cash Convertible Notes Hedges are reported in the consolidated statements of comprehensive income (loss). Year Ended December 31, (In thousands) 2018 2017 Statements of Comprehensive Income (Loss) Classification Cash Convertible Notes Hedges: Net unrealized gain $ 7,167 $ 85,718 Selling, general and administrative expense Cash Conversion Derivative: Net unrealized loss $ (7,167 ) $ (85,718 ) Selling, general and administrative expense
Estimated Gross Fair Values of Derivative Instruments	The estimated gross fair values of derivative instruments at December 31, 2018 and December 31, 2017 were as follows: (In thousands) December 2018 December 2017 Assets: Derivatives not designated as hedging instruments: Cash convertible notes hedges, current $ — $ 134,079 Liabilities: Derivatives not designated as hedging instruments: Cash conversion derivative, current $ — $ 134,079

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2018
Leases [Abstract]
Summary of Future Minimum Lease Payments Under All Non-cancelable Operating Leases	The following table summarizes our future minimum lease payments, net of total cash receipts from subleases of $23.7 million, under all non-cancelable operating leases for each of the next five years and thereafter. As of December 31, 2018, future minimum lease payments under capital leases were not material. (In thousands) Operating Year ending December 31, Leases 2019 $ 4,022 2020 2,040 2021 910 2022 827 2023 136 2024 and thereafter — Total minimum lease payments $ 7,935

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Allocated Share-based Compensation Costs	Following are certain amounts recognized in the consolidated statements of operations for share-based compensation arrangements for the years ended December 31, 2018, 2017, and 2016. We did not capitalize any share-based compensation costs during these periods. Year Ended December December 31, December 31, (In millions) 2018 2017 2016 Total share-based compensation $ 6.1 $ 6.7 $ 17.5 Share-based compensation included in cost of services 2.3 2.2 1.2 Share-based compensation included in selling, general and administrative expenses 3.8 4.4 5.9 Share-based compensation included in restructuring and related charges — 0.1 0.3 Share-based compensation included in discontinued operations (1) — — 10.1 Total income tax benefit recognized 1.6 2.6 2.9 (1) Includes the acceleration of vesting in 2016 of all unvested stock options, market stock units and restricted stock units held by two former senior executives as of the Closing who had accepted employment with Sharecare.
Summary of Weighted Average Grant-date Fair Values of Options and Weighted Average Assumptions Used to Develop Fair Value Estimates	The following table sets forth the weighted average grant-date fair values of options and the weighted average assumptions we used to develop the fair value estimates for the year ended December 31, 2018. There were no stock options granted during fiscal 2017 or 2016. Year Ended December 2018 Weighted average grant-date fair value of options per share $ 20.21 Assumptions: Expected volatility 56.2 % Expected dividends — Expected term (in years) 6.7 Risk-free rate 2.8 %
Summary of Stock Options	A summary of options as of December 31, 2018 and the activity during the year then ended is presented below: Options Shares (In Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding at January 1, 2018 507 $ 12.98 Granted 86 37.94 Exercised (156 ) 12.28 Forfeited (6 ) 39.45 Expired — — Outstanding at December 31, 2018 431 $ 17.83 4.4 $ 4,045 Exercisable at December 31, 2018 351 $ 13.29 3.3 $ 4,045
Summary of Nonvested Shares	The following table shows a summary of our restricted stock units as of December 31, 2018 as well as activity during the year then ended: Restricted Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2018 572 $ 17.60 Granted 74 38.12 Vested (339 ) 16.26 Forfeited (36 ) 24.07 Nonvested at December 31, 2018 271 $ 24.07
Summary of Market Stock Units	The following table shows a summary of our market stock units as of December 31, 2018 as well as activity during the year then ended: Market Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2018 373 $ 9.01 Granted — — Shares adjustment for above-target performance (1) 185 6.80 Vested (474 ) 6.80 Forfeited (39 ) 14.76 Nonvested at December 31, 2018 45 $ 18.25 (1) Represents the number of shares earned in excess of target for certain market stock units that vested during the year. These awards were reported at the target number of shares when granted.

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share	The i e o a u o n i o i d g o s e o ea r e e e 3 17 (In thousands except per share data) Year Ended December 31, Numerator: 2018 2017 2016 Income from continuing operations attributable to Tivity Health, Inc. - numerator for earnings per share $ 97,902 $ 61,230 $ 56,091 Net income (loss) from discontinued operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share 901 2,485 (185,202 ) Net income (loss) attributable to Tivity Health, Inc. - numerator for earnings (loss) per share $ 98,803 $ 63,715 $ (129,111 ) Denominator: Shares used for basic income (loss) per share 40,078 39,357 36,999 Effect of dilutive stock options and restricted stock units outstanding: Non-qualified stock options 264 436 344 Restricted stock units 299 549 538 Warrants related to Cash Convertible Notes 2,013 1,709 — Market stock units 419 496 194 Shares used for diluted income (loss) per share 43,073 42,547 38,075 Earnings (loss) per share attributable to Tivity Health, Inc. - basic: Continuing operations $ 2.44 $ 1.56 $ 1.52 Discontinued operations $ 0.02 $ 0.06 $ (5.01 ) Net income (loss) (1) $ 2.47 $ 1.62 $ (3.49 ) Earnings (loss) per share attributable to Tivity Health, Inc. - diluted: Continuing operations $ 2.27 $ 1.44 $ 1.47 Discontinued operations $ 0.02 $ 0.06 $ (4.86 ) Net earnings (loss) $ 2.29 $ 1.50 $ (3.39 ) Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive: Non-qualified stock options 56 4 708 Restricted stock units 36 12 333 Warrants related to Cash Convertible Notes — — 7,707 (1) Figures may not add due to rounding.

Accumulated OCI (Tables)

Accumulated OCI (Tables)	12 Months Ended
	Dec. 31, 2018
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Changes in Accumulated OCI	The following table summarizes the changes in accumulated OCI, net of tax, for the year ended December 31, 2017: (In thousands) Foreign Currency Translation Adjustments Accumulated OCI, net of tax, as of January 1, 2017 $ (4,502 ) Other comprehensive income before reclassifications, net of tax of $225 1,458 Amounts reclassified from accumulated OCI, net of tax of $0 3,044 (1) Accumulated OCI, net of tax, as of December 31, 2017 $ — (1) This amount was reclassified out of accumulated OCI to gain (loss) on discontinued operations during the year ended December 31, 2017 and had a tax effect of $0.

Quarterly Financial Informati_2

Quarterly Financial Information (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	(In thousands, except per share data) Year Ended December 31, 2018 First Second Third Fourth (1) Revenues $ 149,930 $ 151,865 $ 151,467 $ 153,037 Gross margin 40,678 41,848 43,349 43,601 Income before income taxes 28,493 30,352 34,386 31,717 Income from continuing operations 21,336 22,683 25,357 28,526 Income from discontinued operations, net of income tax — 901 — — Net income 21,336 23,584 25,357 28,526 Earnings per share – basic: Continuing operations (2) $ 0.54 $ 0.57 $ 0.63 $ 0.70 Discontinued operations (2) $ — $ 0.02 $ — $ — Net income (2) (3) $ 0.54 $ 0.59 $ 0.63 $ 0.70 Earnings per share – diluted: Continuing operations (2) $ 0.49 $ 0.52 $ 0.59 $ 0.67 Discontinued operations (2) $ — $ 0.02 $ — $ — Net income (2) (3) $ 0.49 $ 0.54 $ 0.59 $ 0.67 (In thousands, except per share data) Year Ended December 31, 2017 First Second Third Fourth (4) Revenues $ 140,970 $ 138,914 $ 137,703 $ 139,354 Gross margin 37,914 39,195 42,465 38,970 Income before income taxes 24,852 26,800 30,289 22,843 Income from continuing operations 15,481 17,240 19,886 8,624 Income (loss) from discontinued operations, net of income tax (220 ) (3,673 ) 6,519 (141 ) Net income 15,261 13,567 26,405 8,483 Earnings (loss) per share – basic: Continuing operations (2) $ 0.40 $ 0.44 $ 0.50 $ 0.22 Discontinued operations (2) $ (0.01 ) $ (0.09 ) $ 0.17 $ (0.00 ) Net income (2) (3) $ 0.39 $ 0.35 $ 0.67 $ 0.21 Earnings (loss) per share – diluted: Continuing operations (2) $ 0.38 $ 0.41 $ 0.46 $ 0.20 Discontinued operations (2) $ (0.01 ) $ (0.09 ) $ 0.15 $ 0.00 Net income (2) (3) $ 0.38 $ 0.32 $ 0.61 $ 0.20 (1) (2) We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share. (3 ) Figures may not add due to rounding. (4 ) The Tax Act was signed into law during the fourth quarter of 2017, and we incurred a non-cash charge of $7.4 million during the quarter related to both the re-measurement of our deferred tax assets to the lower tax rate

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2018USD ($)Program	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Mar. 11, 2015
Accounting Policies [Line Items]
Number of programs | Program	3
Allowance for doubtful accounts	$ 0	$ 0
Depreciation	4,700,000	3,400,000	$ 3,600,000
Intangible assets not subject to amortization	29,000,000	29,000,000
Accrued liabilities	43,145,000	34,511,000
Network Locations Visits
Accounting Policies [Line Items]
Accrued liabilities	26,100,000	$ 23,100,000
Other obligations	$ 9,800,000
Minimum
Accounting Policies [Line Items]
Estimated useful life	3 years	3 years
Maximum
Accounting Policies [Line Items]
Estimated useful life	10 years	10 years
Computer Software and Hardware | Minimum
Accounting Policies [Line Items]
Useful life	3 years
Computer Software and Hardware | Maximum
Accounting Policies [Line Items]
Useful life	7 years
Furniture and Other Office Equipment | Minimum
Accounting Policies [Line Items]
Useful life	4 years
Furniture and Other Office Equipment | Maximum
Accounting Policies [Line Items]
Useful life	7 years
Leasehold Improvements | Minimum
Accounting Policies [Line Items]
Useful life	2 years
Leasehold Improvements | Maximum
Accounting Policies [Line Items]
Useful life	15 years
SulAmerica
Accounting Policies [Line Items]
Percentage of ownership interest acquired in joint venture				49.00%

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details)	12 Months Ended
	Dec. 31, 2018USD ($)ProgramObligation
Disaggregation Of Revenue [Line Items]
Number of programs | Program	3
Number of performance obligations	1
Number of performance obligation unsatisfied	0
Revenue recognized from performance obligations satisfied in prior period | $	$ 0
Period of billing in arrears once timing of services to customers is known	1 month
Number of days for customer to make payment after being invoiced	30 days
Revenues | Product Concentration Risk | SilverSneakers Program
Disaggregation Of Revenue [Line Items]
Percentage of concentration risk	80.00%
Revenues | Product Concentration Risk | Prime Fitness Program
Disaggregation Of Revenue [Line Items]
Percentage of concentration risk	17.00%
Revenues | Product Concentration Risk | WholeHealth Living Program
Disaggregation Of Revenue [Line Items]
Percentage of concentration risk	3.00%

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) - Sharecare - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Adjustable convertible equity right, face amount			$ 39,800	$ 30,000
Payments Of Claims For Indemnification		$ 0
Adjustable Convertible Equity Right
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Conversion date of stock conversion		Jul. 31, 2018
Stock issued during period conversion of convertible securities, conversion price (in dollars per share)				$ 249.87
Carrying value of adjustable convertible equity right			$ 10,800
Stock obtained during period conversion of convertible securities	159,309

Discontinued Operations - Finan

Discontinued Operations - Financial Results Included in Losses from Discontinued Operations (Details) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
		Jun. 30, 2017	Dec. 31, 2018		Dec. 31, 2017		Dec. 31, 2016
Financial results included in losses from discontinued operations [Abstract]
Pretax loss on release of cumulative translation adjustment					$ (3,044)
Income (loss) from discontinued operations, net of income tax			$ 901		2,485		$ (184,706)
TPHS Business | Discontinued Operations, Disposed of by Sale
Financial results included in losses from discontinued operations [Abstract]
Revenues			0		0		151,780
Cost of services			30		427		173,302
Selling, general & administrative expenses			48		349		18,594
Depreciation and amortization			0		0		27,207
Restructuring and related charges			0		0		8,626
Equity in income from joint ventures			0		98		243
Pretax loss on discontinued operations			(78)		(678)		(75,706)
Pretax loss on release of cumulative translation adjustment		$ (3,000)	0	[1]	(3,044)	[1]	0	[1]
Pretax gain (loss) on sale of MeYou Health business	[2]		1,416		0		(4,826)
Pretax income (loss) on sale of TPHS business			(112)		4,733		(202,095)
Total pretax income (loss) on discontinued operations			1,226		1,011		(282,627)
Income tax expense (benefit)	[3]		325		(1,474)		(97,921)
Income (loss) from discontinued operations, net of income tax			$ 901		$ 2,485		$ (184,706)
[1]	During the second quarter of 2017, we substantially liquidated foreign entities that were part of our TPHS business, resulting in a release of the cumulative translation adjustment of $3.0 million into loss from discontinued operations.
[2]	Includes $1.4 million received during the three months ended June 30, 2018 from a release of escrow funds related to the sale of MeYou Health, LLC in June 2016.
[3]	Income tax benefit for the year ended December 31, 2017 includes the effect of a change in the estimate of net U.S. tax incurred in 2016 on foreign activity classified as discontinued operations.

Discontinued Operations - Fin_2

Discontinued Operations - Financial Results Included in Losses from Discontinued Operations (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2018		Dec. 31, 2017		Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on release of cumulative translation adjustment					$ 3,044
Proceeds from release of escrow funds related to sale of MeYou Health	$ 1,400		$ 1,416				$ 5,156
TPHS Business | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on release of cumulative translation adjustment		$ 3,000	$ 0	[1]	$ 3,044	[1]	$ 0	[1]
[1]	During the second quarter of 2017, we substantially liquidated foreign entities that were part of our TPHS business, resulting in a release of the cumulative translation adjustment of $3.0 million into loss from discontinued operations.

Discontinued Operations - Depre

Discontinued Operations - Depreciation, Amortization and Significant Operating and Investing Non-cash Items of the Discontinued Operations (Details) - TPHS Business - Discontinued Operations, Disposed of by Sale - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Significant operating and investing non-cash items of the discontinued operations [Abstract]
Depreciation and amortization	$ 0	$ 0	$ 27,207
Capital expenditures	0	0	10,258
Share-based compensation	$ 0	$ 0	$ 10,144

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property Plant And Equipment [Line Items]
Total property and equipment at cost	$ 47,052	$ 39,191
Less: accumulated depreciation	(30,711)	(28,533)
Total property and equipment, net	16,341	10,658
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment at cost	10,404	10,384
Computer Equipment and Related Software
Property Plant And Equipment [Line Items]
Total property and equipment at cost	22,200	19,508
Furniture and Office Equipment
Property Plant And Equipment [Line Items]
Total property and equipment at cost	8,053	8,194
Capital Projects in Process
Property Plant And Equipment [Line Items]
Total property and equipment at cost	$ 6,395	$ 1,105

Goodwill - Additional Informati

Goodwill - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Goodwill [Roll Forward]
Change in carrying amount of goodwill	$ 0	$ 0
Goodwill, gross	517,000,000	517,000,000
Goodwill, impaired, accumulated impairment loss	$ 182,400,000	$ 182,400,000

Intangible Assets - Intangible

Intangible Assets - Intangible Assets Subject to Amortization (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 10,192	$ 10,442
Accumulated Amortization	(10,192)	(10,442)
Total	0	0
Acquired technology
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,483	1,733
Accumulated Amortization	(1,483)	(1,733)
Total	0	0
Distributor and Provider Networks
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	8,709	8,709
Accumulated Amortization	(8,709)	(8,709)
Total	$ 0	$ 0

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Intangible Assets Net Excluding Goodwill [Abstract]
2,019	$ 0
2,020	0
2,021	0
2,022	0
2,023	0
Thereafter	0
Amortization expense	0	$ 0	$ 500
Intangible assets not subject to amortization	$ 29,000	$ 29,000

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current taxes [Abstract]
Federal	$ 29	$ 771	$ (426)
State	1,857	373	311
Deferred taxes [Abstract]
Federal	20,136	37,565	18,910
State	5,024	4,844	3,178
Total	$ 27,046	$ 43,553	$ 21,973

Income Taxes - Significant Comp

Income Taxes - Significant Components of Net Deferred Tax Asset and Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax asset [Abstract]
Accruals and reserves	$ 769	$ 1,539
Deferred compensation	496	1,439
Share-based payments	2,111	2,944
Net operating loss carryforwards	9,430	32,122
Capital loss carryforwards	7,620	8,102
Cash Conversion Derivative	0	25,821
Tax credits	6,437	6,994
Other assets	0	320
Deferred tax assets, gross	26,863	79,281
Valuation allowance	(10,457)	(11,462)
Total	16,406	67,819
Deferred tax liability [Abstract]
Property and equipment	(2,600)	(2,104)
Intangible assets	(14,125)	(14,728)
Cash Convertible Notes Hedges	0	(25,821)
Total	(16,725)	(42,653)
Net long-term deferred tax (liability)	$ (319)
Net long-term deferred tax asset (liability)		$ 25,166

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	Jan. 01, 2017	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
Tax expense necessary to revalue deferred tax assets and liabilities		$ 5,000,000
Federal corporate tax rate			21.00%
Capital loss carryforwards		8,102,000	$ 7,620,000	$ 8,102,000
Increase (decrease) in valuation allowance			1,000,000
Valuation allowance		$ 11,462,000	10,457,000	11,462,000
Amount of operating loss carryforwards subject to an annual limitation			1,400,000
Tax expense recorded to adjust deferred tax assets due to mandatory deemed repatriation of undistributed foreign earnings				2,500,000
Undistributed earnings of foreign subsidiaries			0
Decrease in unrecognized tax benefits due to settlements of a tax audit			644,000
Unrecognized tax benefits that affect our effective tax rate			0
Interest and penalties related to unrecognized tax benefits			0	$ 0	$ 0
Accounting Standards Update 2016-09 [Member]
Operating Loss Carryforwards [Line Items]
Increase in deferred tax assets as a cumulative-effect adjustment to retained earnings	$ 6,500,000
Capital Loss Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards			$ 30,500,000
Tax credit carryforwards, expiration dates			Dec. 31, 2021
Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Open tax year			2,015
International
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards valuation allowance			$ 2,400,000
Operating loss carryforwards			8,000,000
International | Capital Loss Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards			$ 4,600,000
International | Earliest Tax Year | Capital Loss Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards, expiration dates			Dec. 31, 2022
International | Latest Tax Year | Capital Loss Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards, expiration dates			Dec. 31, 2027
State
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards valuation allowance			$ 500,000
Operating loss carryforwards			$ 105,100,000
State | Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates			Dec. 31, 2021
State | Latest Tax Year
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates			Dec. 31, 2037
Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			$ 5,200,000
Operating loss carryforwards, expiration dates			Dec. 31, 2037

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Difference Between Income Tax Expense Computed Using Statutory Federal Income Tax Rate And Effective Rate [Abstract]
Statutory federal income tax	$ 26,239	$ 36,674	$ 27,321
State income taxes, less federal income tax benefit	6,261	5,119	3,801
Permanent items	1,496	1,750	954
Change in valuation allowance	(1,005)		(9,615)
Share-based compensation	(6,378)	(6,441)
Tax Act adjustments		7,442
Change in uncertain tax position liability	(644)
Prior year tax adjustments	(590)	(544)	(444)
Net impact of foreign operations	990
State income tax credits	677	(447)	(44)
Total	$ 27,046	$ 43,553	$ 21,973

Income Taxes - Uncertain Tax Po

Income Taxes - Uncertain Tax Positions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Changes in Unrecognized Tax Benefits [Roll Forward]
Balance, beginning of period	$ 644	$ 0
Increases based upon tax positions related to prior years		644
Balance, end of period		$ 644
Decreases based upon settlements with taxing authorities	$ (644)

Debt - Summary of Debt, Net of

Debt - Summary of Debt, Net of Unamortized Deferred Loan Costs (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Debt, net of unamortized discount	$ 30,646	$ 146,410
Less: deferred loan costs		(451)
Total debt	30,646	145,959
Less: current portion	(57)	(145,959)
Long-term debt	30,589
Delayed Draw Term Loan Facility
Debt Instrument [Line Items]
Debt, net of unamortized discount	25,000
Revolving Credit Facility
Debt Instrument [Line Items]
Debt, net of unamortized discount	5,450
Cash Convertible Notes, Net of Unamortized Discount
Debt Instrument [Line Items]
Debt, net of unamortized discount		145,861
Capital Lease Obligations and Other
Debt Instrument [Line Items]
Debt, net of unamortized discount	$ 196	$ 549

Debt - Credit Facility - Additi

Debt - Credit Facility - Additional Information (Details) - USD ($)	Apr. 21, 2017	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jul. 02, 2018	Jul. 16, 2013
Line Of Credit Facility [Line Items]
Long term debt outstanding		$ 30,646,000		$ 30,646,000	$ 145,959,000
Repayments Of Long Term Debt				$ 373,536,000	$ 449,084,000	$ 527,115,000
1.50% Cash Convertible Senior Notes Due 2018
Line Of Credit Facility [Line Items]
Debt instrument, face amount								$ 150,000,000
Maturity date				Jul. 2, 2018
Revolving Credit Facility
Line Of Credit Facility [Line Items]
Total availability under the revolving credit facility		88,800,000		$ 88,800,000
Credit Agreement
Line Of Credit Facility [Line Items]
Initiation date				Apr. 21, 2017
Maturity date				Apr. 21, 2022
Credit Agreement | Minimum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage	0.20%
Credit Agreement | Maximum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage	0.50%
Credit Agreement | LIBOR | Minimum
Line Of Credit Facility [Line Items]
Variable rate basis	0.00%
Margin rate	1.50%
Credit Agreement | LIBOR | Maximum
Line Of Credit Facility [Line Items]
Margin rate	2.75%
Credit Agreement | Federal Funds Rate
Line Of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
Credit Agreement | One-Month LIBOR
Line Of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Credit Agreement | Base Rate | Minimum
Line Of Credit Facility [Line Items]
Margin rate	0.50%
Credit Agreement | Base Rate | Maximum
Line Of Credit Facility [Line Items]
Margin rate	1.75%
Credit Agreement | Revolving Credit Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 100,000,000
Credit Agreement | Swingline Sub Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	25,000,000
Credit Agreement | Letters of Credit Sub Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	75,000,000
Credit Agreement | Term Loan Facility A
Line Of Credit Facility [Line Items]
Debt instrument, face amount	70,000,000
Credit Agreement | Delayed Draw Term Loan Facility
Line Of Credit Facility [Line Items]
Debt instrument, face amount	$ 150,000,000
Repayments Of Long Term Debt		$ 75,000,000	$ 75,000,000
Credit Agreement | Delayed Draw Term Loan Facility | First 6 Quarters Following the Time of Borrowing
Line Of Credit Facility [Line Items]
Periodic principal payment as percentage of aggregate principal amount	1.25%
Credit Agreement | Delayed Draw Term Loan Facility | Remaining Quarters Prior to Maturity
Line Of Credit Facility [Line Items]
Periodic principal payment as percentage of aggregate principal amount	1.875%
Credit Agreement | Delayed Draw Term Loan Facility | 1.50% Cash Convertible Senior Notes Due 2018
Line Of Credit Facility [Line Items]
Long term debt outstanding							$ 100,000,000
Credit Agreement | Uncommitted Incremental Accordion Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 100,000,000

Debt - Cash Convertible Notes -

Debt - Cash Convertible Notes - Additional Information (Details) - USD ($)	Oct. 01, 2018	Jul. 02, 2018	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jul. 31, 2013	Jul. 16, 2013
Debt Instrument [Line Items]
Interest expense related to amortization of debt discount				$ 4,140,000	$ 8,001,000	$ 7,564,000
Number of trading days, warrants automatically exercised on a pro rata basis	160 days
Number of warrants are automatically exercised on each trading day	48,000
Common Stock
Debt Instrument [Line Items]
Common stock shares issued related to automatic exercise of warrants			627,000	627,000
Common Stock | Cash Convertible Notes Hedge | Warrants
Debt Instrument [Line Items]
Shares issued upon conversion of debt							7,700,000
Delayed Draw Term Loan Facility
Debt Instrument [Line Items]
Proceeds from borrowings		$ 100,000,000
1.50% Cash Convertible Senior Notes Due 2018
Debt Instrument [Line Items]
Aggregate principal of convertible notes								$ 150,000,000
Interest rate for notes								1.50%
Maturity date				Jul. 2, 2018
Interest expense related to amortization of debt discount				$ 4,100,000	8,000,000
Effective interest rate			5.70%	5.70%
Interest expense				$ 1,100,000	$ 2,300,000	$ 2,300,000
Repayments of debt		150,000,000
Warrants strike price (in dollars per share)							$ 25.95
Cash Conversion Derivative
Debt Instrument [Line Items]
Repayments of debt		$ 141,200,000

Debt - Minimum Annual Principal

Debt - Minimum Annual Principal Payments and Repayments of the Revolving Advances (Details) $ in Thousands	Dec. 31, 2018USD ($)
Minimum annual principal payments and repayments of the revolving advances [Abstract]
2,019	$ 0
2,020	0
2,021	0
2,022	30,450
2,023	0
2024 and thereafter	0
Total	$ 30,450

Commitments and Contingencies -

Commitments and Contingencies - Additional Information - (Details)	Nov. 06, 2017Lawsuit
Commitments And Contingencies Disclosure [Abstract]
Number of lawsuits filed	3

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) $ in Thousands	Dec. 31, 2018USD ($)
Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 1,900
Cash Convertible Notes Hedges and Cash Conversion Derivative
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets and liabilities measured at fair value on a recurring basis	0
Credit Agreement
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument fair value	30,100
Debt instrument carrying amount	$ 30,500

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments Measured at Fair Value on Recurring Basis Using Unobservable Inputs (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Cash Convertible Notes Hedge
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance at beginning of period	$ 134,079
Settlements of Level 3 Instruments	(141,246)
Gains (Losses) Included in Earnings	7,167
Cash Conversion Derivative
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance at beginning of period	(134,079)
Settlements of Level 3 Instruments	141,246
Gains (Losses) Included in Earnings	$ (7,167)

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Gains and Losses from Change in Fair Values of Derivatives (Details) - Selling, General and Administrative Expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash Convertible Notes Hedge
Net unrealized gain (loss) on derivative instruments not designated as hedging instruments [Abstract]
Net unrealized gain (loss)	$ 7,167	$ 85,718
Cash Conversion Derivative
Net unrealized gain (loss) on derivative instruments not designated as hedging instruments [Abstract]
Net unrealized gain (loss)	$ (7,167)	$ (85,718)

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Estimated Gross Fair Values of Derivative Instruments (Details) $ in Thousands	Dec. 31, 2017USD ($)
Liabilities:
Cash conversion derivative	$ 134,079
Cash Convertible Notes Hedge | Derivatives Not Designated as Hedging Instruments
Assets:
Derivative assets, current	134,079
Cash Conversion Derivative | Derivatives Not Designated as Hedging Instruments
Liabilities:
Cash conversion derivative	$ 134,079

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018USD ($)ft²RenewalOption	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Operating Leased Assets [Line Items]
Rent expense	$ 2.7	$ 2.5	$ 4.2
Total cash receipts from subleases	$ 23.7
Franklin, Tennessee
Operating Leased Assets [Line Items]
Area of leased property | ft²	264,000
Area of leased property, sublease | ft²	221,000
Lease expiration date	Feb. 28, 2023
Number of renewal options | RenewalOption	2
Renewal options period	5 years
Operating lease term	15 years
Tenant improvement allowance	$ 10.7
Franklin, Tennessee | Minimum
Operating Leased Assets [Line Items]
Rent expense	4.3
Franklin, Tennessee | Maximum
Operating Leased Assets [Line Items]
Rent expense	$ 6.6
Chandler, Arizona
Operating Leased Assets [Line Items]
Area of leased property | ft²	92,000
Lease expiration date	Apr. 30, 2020
Ashburn, Virginia
Operating Leased Assets [Line Items]
Area of leased property | ft²	6,000

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments Under All Non-cancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2018USD ($)
Future minimum lease payments under operating leases [Abstract]
2,019	$ 4,022
2,020	2,040
2,021	910
2,022	827
2,023	136
Total minimum lease payments	$ 7,935

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)TypeEmployee$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Types of share based awards | Type	3
Number of shares reserved for future equity grants (in shares) | shares	1,200,000
Total unrecognized compensation cost related to nonvested share-based compensation arrangements granted	$ 4,900
Weighted average period for recognition of unrecognized compensation cost	1 year 2 months 12 days
Stock options granted during period | shares	86,000	0	0
Total intrinsic value of options exercised during period	$ 3,900	$ 10,500	$ 10,200
Cash received from option exercised	1,910	5,722	10,002
Tax benefit realized from options exercised	1,000
Total grant-date fair value of shares vested	$ 7,600	$ 5,700	$ 13,900
TPHS Business
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of employees considered for accelerating vesting dates to closing date | Employee	100
Modification cost	$ 7,400
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	4 years
Expiration period	10 years
Employee Stock Option | TPHS Business
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Modified shares (in shares) | shares			92,000
Restricted Stock and Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted (in dollars per share) | $ / shares	$ 38.12	$ 32.06	$ 12.37
Restricted Stock and Restricted Stock Units (RSUs) | TPHS Business
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Modified shares (in shares) | shares			396,000
Restricted Stock and Restricted Stock Units (RSUs) | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	3 years
Restricted Stock and Restricted Stock Units (RSUs) | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	4 years
Performance-based Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	3 years
Market Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted (in dollars per share) | $ / shares	$ 0	$ 0	$ 10.67
Market Stock Units | TPHS Business
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Modified shares (in shares) | shares			75,000

Share-Based Compensation - Allo

Share-Based Compensation - Allocated Share-based Compensation Costs (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs		$ 6.1	$ 6.7	$ 17.5
Total income tax benefit recognized		1.6	2.6	2.9
Discontinued Operations
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs	[1]			10.1
Cost of Services
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs		2.3	2.2	1.2
Selling, General and Administrative Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs		$ 3.8	4.4	5.9
Restructuring and Related Charges
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs			$ 0.1	$ 0.3
[1]	Includes the acceleration of vesting in 2016 of all unvested stock options, market stock units and restricted stock units held by two former senior executives as of the Closing who had accepted employment with Sharecare.

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Weighted Average Grant-date Fair Values of Options and Weighted Average Assumptions Used to Develop Fair Value Estimates (Details)	12 Months Ended
	Dec. 31, 2018$ / shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options per share	$ 20.21
Assumptions:
Expected volatility	56.20%
Expected term (in years)	6 years 8 months 12 days
Risk-free rate	2.80%

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Shares [Roll Forward]
Outstanding, beginning of period (in shares)	507,000
Granted (in shares)	86,000	0	0
Exercised (in shares)	(156,000)
Forfeited (in shares)	(6,000)
Outstanding, end of period (in shares)	431,000	507,000
Exercisable, end of period (in shares)	351,000
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 12.98
Granted (in dollars per share)	37.94
Exercised (in dollars per share)	12.28
Forfeited (in dollars per share)	39.45
Outstanding, end of period (in dollars per share)	17.83	$ 12.98
Exercisable, end of period (in dollars per share)	$ 13.29
Weighted-Average Remaining Contractual Term [Abstract]
Outstanding	4 years 3 months 18 days
Exercisable	3 years 3 months 18 days
Aggregate Intrinsic Value [Abstract]
Outstanding, end of period	$ 4,045
Exercisable, end of period	$ 4,045

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Nonvested Shares (Details) - Restricted Stock Units - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Shares [Roll Forward]
Nonvested, beginning of period (in shares)	572
Granted (in shares)	74
Vested (in shares)	(339)
Forfeited (in shares)	(36)
Nonvested, end of period (in shares)	271	572
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share)	$ 17.60
Granted (in dollars per share)	38.12	$ 32.06	$ 12.37
Vested (in dollars per share)	16.26
Forfeited (in dollars per share)	24.07
Nonvested, end of period (in dollars per share)	$ 24.07	$ 17.60

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Market Stock Units (Details) - Market Stock Units - $ / shares shares in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Shares [Roll Forward]
Nonvested, beginning of period (in shares)		373
Shares adjustment for above-target performance	[1]	185
Vested (in shares)		(474)
Forfeited (in shares)		(39)
Nonvested, end of period (in shares)		45	373
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share)		$ 9.01
Granted (in dollars per share)		0	$ 0	$ 10.67
Shares adjustment for above-target performance	[1]	6.80
Vested (in dollars per share)		6.80
Forfeited (in dollars per share)		14.76
Nonvested, end of period (in dollars per share)		$ 18.25	$ 9.01
[1]	Represents the number of shares earned in excess of target for certain market stock units that vested during the year. These awards were reported at the target number of shares when granted.

Earnings (Loss) Per Share - Rec

Earnings (Loss) Per Share - Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended																12 Months Ended
		Dec. 31, 2018	[1]	Sep. 30, 2018		Jun. 30, 2018		Mar. 31, 2018		Dec. 31, 2017	[2]	Sep. 30, 2017		Jun. 30, 2017		Mar. 31, 2017		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Numerator [Abstract]
Income from continuing operations attributable to Tivity Health, Inc. - numerator for earnings per share		$ 28,526		$ 25,357		$ 22,683		$ 21,336		$ 8,624		$ 19,886		$ 17,240		$ 15,481		$ 97,902	$ 61,230	$ 56,091
Net income (loss) from discontinued operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share						901				(141)		6,519		(3,673)		(220)		901	2,485	(185,202)
Net income (loss) attributable to Tivity Health, Inc.		$ 28,526		$ 25,357		$ 23,584		$ 21,336		$ 8,483		$ 26,405		$ 13,567		$ 15,261		$ 98,803	$ 63,715	$ (129,111)
Denominator [Abstract]
Shares used for basic income (loss) per share																		40,078	39,357	36,999
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Shares used for diluted income (loss) per share																		43,073	42,547	38,075
Earnings (loss) per share attributable to Tivity Health, Inc. - basic [Abstract]
Continuing operations (in dollars per share)		$ 0.70	[3]	$ 0.63	[3]	$ 0.57	[3]	$ 0.54	[3]	$ 0.22	[3]	$ 0.50	[3]	$ 0.44	[3]	$ 0.40	[3]	$ 2.44	$ 1.56	$ 1.52
Discontinued operations (in dollars per share)						0.02	[3]			0	[3]	0.17	[3]	(0.09)	[3]	(0.01)	[3]	0.02	0.06	(5.01)
Net income (loss)	[4]	0.70	[3]	0.63	[3]	0.59	[3]	0.54	[3]	0.21	[3]	0.67	[3]	0.35	[3]	0.39	[3]	2.47	1.62	(3.49)
Earnings (loss) per share attributable to Tivity Health, Inc. - diluted [Abstract]
Continuing operations (in dollars per share)		0.67	[3]	0.59	[3]	0.52	[3]	0.49	[3]	0.20	[3]	0.46	[3]	0.41	[3]	0.38	[3]	2.27	1.44	1.47
Discontinued operations (in dollars per share)						0.02	[3]			0	[3]	0.15	[3]	(0.09)	[3]	(0.01)	[3]	0.02	0.06	(4.86)
Net income (loss)		$ 0.67	[3],[4]	$ 0.59	[3],[4]	$ 0.54	[3],[4]	$ 0.49	[3],[4]	$ 0.20	[3],[4]	$ 0.61	[3],[4]	$ 0.32	[3],[4]	$ 0.38	[3],[4]	$ 2.29	$ 1.50	$ (3.39)
Non-Qualified Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)																		56	4	708
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)																		36	12	333
Warrants Related to Cash Convertible Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)																				7,707
Non-Qualified Stock Options
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																		264	436	344
Restricted Stock Units
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																		299	549	538
Warrants Related to Cash Convertible Notes
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																		2,013	1,709
Market Stock Units
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																		419	496	194
[1]	During the fourth quarter of 2018, we incurred $3.3 million of project costs in connection with potential and pending acquisitions, which were recorded to selling, general, and administrative expenses. In addition, our effective tax rate for the fourth quarter of 2018 of 10.1% was lower than our statutory rate primarily due to positive tax benefits of $4.6 million related to the vesting of stock-based compensation awards during the quarter.
[2]	The Tax Act was signed into law during the fourth quarter of 2017, and we incurred a non-cash charge of $7.4 million during the quarter related to both the re-measurement of our deferred tax assets to the lower tax rate
[3]	We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share.
[4]	Figures may not add due to rounding.

Accumulated OCI - Changes in Ac

Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Details) - Foreign Currency Translation Adjustments $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Changes in accumulated OCI, net of tax [Roll Forward]
Balance	$ (4,502)
Other comprehensive income (loss) before reclassifications, net	1,458
Amounts reclassified from accumulated OCI, net of tax	3,044	[1]
Balance	$ 0
[1]	This amount was reclassified out of accumulated OCI to gain (loss) on discontinued operations during the year ended December 31, 2017 and had a tax effect of $0.

Accumulated OCI - Changes in _2

Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Parenthetical) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Other comprehensive income before reclassifications, tax		$ 225
Amounts reclassified from accumulated OCI, tax	$ 0	0
Amounts reclassified from accumulated OCI to gain (loss), tax effect		$ 0

Accumulated OCI - Additional In

Accumulated OCI - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Amounts reclassified from accumulated OCI, tax	$ 0	$ 0

Segment Disclosures and Conce_2

Segment Disclosures and Concentrations of Risk - Additional Information (Details)	12 Months Ended
	Dec. 31, 2018SegmentCustomer	Dec. 31, 2017SegmentCustomer
Revenue, Major Customer [Line Items]
Number of reportable segments | Segment	1	1
Percentage of long-lived assets and revenue from external customers in united states	100.00%	100.00%
Customer Concentration Risk | Revenues
Revenue, Major Customer [Line Items]
Number of largest individual customers | Customer	3	2
Customer Concentration Risk | Revenues | Customer One
Revenue, Major Customer [Line Items]
Percentage of concentration risk	20.00%	20.30%
Customer Concentration Risk | Revenues | Customer Two
Revenue, Major Customer [Line Items]
Percentage of concentration risk	14.60%	17.40%
Customer Concentration Risk | Revenues | Customer Three
Revenue, Major Customer [Line Items]
Percentage of concentration risk	10.00%
Customer Concentration Risk | Accounts Receivable, Net | Customer One
Revenue, Major Customer [Line Items]
Percentage of concentration risk	26.00%	31.00%
Customer Concentration Risk | Accounts Receivable, Net | Customer Two
Revenue, Major Customer [Line Items]
Percentage of concentration risk	13.00%	11.00%

Pending Acquisition of Nutris_2

Pending Acquisition of Nutrisystem - Additional Information (Details) - USD ($)	Dec. 09, 2018	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Common stock, par value (in dollars per share)		$ 0.001	$ 0.001
Debt Commitment Letter | Senior Secured Term Loan Facility
Business Acquisition [Line Items]
Maximum borrowing capacity	$ 1,210,000,000
Debt Commitment Letter | Senior Secured Revolving Credit Facility
Business Acquisition [Line Items]
Maximum borrowing capacity	$ 125,000,000
Nutrisystem, Inc. and Sweet Acquisition, Inc. | Merger Agreement
Business Acquisition [Line Items]
Business acquisition, agreement date	Dec. 9, 2018
Common stock, par value (in dollars per share)	$ 0.001
Business acquisition, cash received in conversion	$ 38.75
Business acquisition, share issued in conversion	0.2141

Quarterly Financial Informati_3

Quarterly Financial Information (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended																12 Months Ended
		Dec. 31, 2018	[1]	Sep. 30, 2018		Jun. 30, 2018		Mar. 31, 2018		Dec. 31, 2017	[2]	Sep. 30, 2017		Jun. 30, 2017		Mar. 31, 2017		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Revenues		$ 153,037		$ 151,467		$ 151,865		$ 149,930		$ 139,354		$ 137,703		$ 138,914		$ 140,970		$ 606,299	$ 556,942	$ 500,998
Gross margin		43,601		43,349		41,848		40,678		38,970		42,465		39,195		37,914
Income before income taxes		31,717		34,386		30,352		28,493		22,843		30,289		26,800		24,852		124,948	104,783	78,064
Net income from continuing operations		28,526		25,357		22,683		21,336		8,624		19,886		17,240		15,481		97,902	61,230	56,091
Net income (loss) from discontinued operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share						901				(141)		6,519		(3,673)		(220)		901	2,485	(185,202)
Net income		$ 28,526		$ 25,357		$ 23,584		$ 21,336		$ 8,483		$ 26,405		$ 13,567		$ 15,261		$ 98,803	$ 63,715	$ (129,111)
Earnings (loss) per share attributable to Tivity Health, Inc. - basic:
Continuing operations		$ 0.70	[3]	$ 0.63	[3]	$ 0.57	[3]	$ 0.54	[3]	$ 0.22	[3]	$ 0.50	[3]	$ 0.44	[3]	$ 0.40	[3]	$ 2.44	$ 1.56	$ 1.52
Discontinued operations						0.02	[3]			0	[3]	0.17	[3]	(0.09)	[3]	(0.01)	[3]	0.02	0.06	(5.01)
Net income (loss)	[4]	0.70	[3]	0.63	[3]	0.59	[3]	0.54	[3]	0.21	[3]	0.67	[3]	0.35	[3]	0.39	[3]	2.47	1.62	(3.49)
Earnings (loss) per share attributable to Tivity Health, Inc. – diluted:
Continuing operations		0.67	[3]	0.59	[3]	0.52	[3]	0.49	[3]	0.20	[3]	0.46	[3]	0.41	[3]	0.38	[3]	2.27	1.44	1.47
Discontinued operations						0.02	[3]			0	[3]	0.15	[3]	(0.09)	[3]	(0.01)	[3]	0.02	0.06	(4.86)
Net income		$ 0.67	[3],[4]	$ 0.59	[3],[4]	$ 0.54	[3],[4]	$ 0.49	[3],[4]	$ 0.20	[3],[4]	$ 0.61	[3],[4]	$ 0.32	[3],[4]	$ 0.38	[3],[4]	$ 2.29	$ 1.50	$ (3.39)
[1]	During the fourth quarter of 2018, we incurred $3.3 million of project costs in connection with potential and pending acquisitions, which were recorded to selling, general, and administrative expenses. In addition, our effective tax rate for the fourth quarter of 2018 of 10.1% was lower than our statutory rate primarily due to positive tax benefits of $4.6 million related to the vesting of stock-based compensation awards during the quarter.
[2]	The Tax Act was signed into law during the fourth quarter of 2017, and we incurred a non-cash charge of $7.4 million during the quarter related to both the re-measurement of our deferred tax assets to the lower tax rate
[3]	We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share.
[4]	Figures may not add due to rounding.

Quarterly Financial Informati_4

Quarterly Financial Information (unaudited) (Parenthetical) (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Effective tax rate	10.10%
Tax benefits related to vesting of stock-based compensation awards	$ 4.6
Non-cash charge related to both re-measurement of deferred tax assets to lower tax rate and repatriation of foreign earnings		$ 7.4
Selling, General and Administrative Expenses
Project costs incurred in connection to potential and pending acquistions	$ 3.3